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Abstract
The human antimicrobial peptide cathelicidin acts as effector molecule of
the innate immune system with direct antimicrobial and immunomodulatory
functions. The aim of this study was to test whether the cathelicidin LL-37
modulates the response of neutrophils to microbial stimulation. Furthermore
we wanted to investigate whether the presence of cathelicidin reduces pul-
monary emphysema and enhances of pulmonary epithelial repair after acute
lung injury induced by naphthalene.
Human neutrophils were stimulated with LPS, Staphylococcus aureus and
Pseudomonas aeruginosa following incubation with LL-37. Cytokine release
was measured by ELISA. Reactive Oxygen Species (ROS) production of neu-
trophils was determined by luminometric and a flow cytometric methods.
Peritoneal mouse neutrophils isolated from CRAMP deficient and wildtype
animals were treated with LPS and TNF-α was measured in the supernatant
by ELISA. Antimicrobial activity of neutrophils was detected by incubating
neutrophils isolated from CRAMP knockout and wildtype mice with bacte-
ria. Pulmonary emphysema was induced in mice by intratracheal instillation
of elastase and induction of emphysema was evaluated depending on morpho-
logical parameter like mean linear intercept (Lm).
To test whether cathelicidin enhances lung tissue repair, a selective in-
jury was induced to mouse nonciliated bronchiolar epithelial cells (clara) with
naphthalene. The repair of clara cells were determined by immunohistochem-
ical staining for CC10 protein. Incubation with LL-37 significantly decreased
the release of proinflammatory cytokines from human neutrophils stimulated
with TLR ligands or whole bacteria. LL-37 induced the production of ROS
and the increased engulfment of bacteria into neutrophils. Neutrophils from
CRAMP deficient mice released significantly more TNF-α after LPS stimula-
tion and showed decreased antimicrobial activity as compared to cells from
wildtype animals.
Absence of cathelicidin in CRAMP deficient mice decreases significantly
the repair of airway epithelium and increases the induction of pulmonary
emphysema-induced by application of elastase. In conclusion, LL-37 modu-
lates the response of various innate immune mechanisms involved in tissue
homeostasis and inflammation. Cathelicidin controls the release of inflamma-
tory mediators while increasing neutrophils antimicrobial activity.
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Zusammenfassung
Das menschliche antimikrobielle Peptid Cathelicidin fungiert als Effektor-
Molekül des angeborenen Immunsystems mit direkten antimikrobiellen und
immunmodulatorischen Funktionen. LL-37 ist das einzige Cathelicidin des
Menschen. Ziel dieser Studie war es zu prüfen, ob Cathelicidin die Antwort
neutrophiler Granulozyten auf mikrobielle Stimulation moduliert. Wir un-
tersuchten außerdem, ob bei akutem Lungenversagen, dass durch Naphthalin
induziert wurde, die Anwesenheit von Cathelicidin das Auftreten eines Lun-
genemphysems reduziert und die Regenerationsfähigkeit pulmonaler Epithelze-
llen erhöht. Neutrophile Granulozyten wurden mit LPS, Staphylococcus au-
reus und Pseudomonas aeruginosa nach Inkubation mit LL-37 stimuliert. Die
Zytokin-Produktion wurde per ELISA gemessen. Die Produktion reaktiver
Sauerstoffspezies (ROS) von Neutrophilen wurde über Luminometrie und ein
Flowzytometrsche Methoden bestimmt. Neutrophile wurden aus dem Peri-
toneum von CRAMP defizienten und Wildtyp-Mäusen isoliert und mit LPS
stimuliert. TNF-α wurde per ELISA im Überstand gemessen. Die Inkubation
mit LL-37 führt zu einer deutlich verringerten Freisetzung von proinflamma-
torischen Zytokinen durch humane Neutrophile, die mit TLR-Liganden oder
ganzen Bakterien angeregt wurden. Ein Lungenemphysem wurde in Mäusen
durch intratracheae Installation von Elastase induziert und die Induktion des
Emphysem über morphologische Parameter wie den mittleren linear Intercept
(Lm) analysiert. Um zu testen, ob Cathelicidin die Regenerationsfähigkeit
von Lungengewebe erhöht, wurde eine selektive Schädigung muriner bronchi-
olärer Clara-Zellen durch Naphthalin induziert. Die Regenerationsfähigkeit
von Clara-Zellen wurden durch Bestimmung der Zellzahl immunhistochemis-
che Färbungen für CC10-Protein bestimmt. LL-37 induziert die Produktion
von ROS und die zunehmende Phagozytose von Bakterien in Neutrophile.
Neutrophile aus CRAMP-defizienten Mäusen gegeben deutlich mehr TNF-α
nach LPS-Stimulation frei und weisen eine verringerte antimikrobielle Aktiv-
ität im Vergleich zu Neutrophilen aus Wildtyp-Tiere auf. Das Fehlen von
Cathelicidin in CRAMP defizienten Mäusen führt zu signifikant verringerter
Regenerationsfähigkeit von Epithelzellen der Atemwege und begünstigt die
Entstehung eines durch Elastase induzierten Lungenemphysems. Zusammen-
fassend ist festzustellen, dass LL-37 die Reaktion verschiedener Mechanismen
des angeborenen Immunsystems moduliert, die an der Gewebshomöostase und
der Entstehung von Entzündungen beteiligt sind. Cathelicidin steuert die
Freisetzung von Entzündungsmediatoren bei gleichzeitiger Erhöhung der an-
timikrobiellen Aktivität neutrophiler Granulozyten antimikrobielle Aktivität.
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Introduction
1 Introduction
1.1 General features of innate immunity
The human immune system differentiates between self and non-self, and this
ability protects the body from the invasion of different pathogens and helps to
eliminate altered cells. The immune system has been classified into two different
branches titled adaptive and innate immunity (Figure 1.1.1).
Figure 1.1.1: Classical classification of human immune system. Human immune system was classified
depending on its specificity responses into innate and adaptive immune. Each of these two different branches has
own humoral and cellular components. Innate immune exists in the human body from birth and is found in variable
plants and animals. Innate immune is considered the first line defense responses to pathogens.
The first line of defense which is also called nonspecific defense is provided by
different natural factors such as skin, bactericidal gland secretions and the mucocil-
iary elevator of the mucosal surfaces (Figure 1.1.2) . This defense is essential and
protects the body against dangers regardless of their nature. However, this type
of defense mechanism is not sufficient, when the microbe escapes from it, there-
fore a second line of defense is needed to immediately recognize the pathogen after
it crosses the barriers. This recognition system must also have the ability to dis-
criminate pathogens from self. This kind of defense response can be called innate
immunity because it exists in the body from birth and is based on discrimination of
“nonself” from “self”, that is a classical property of immune system [103]. Adaptive
immunity distinguishes itself from the innate immunity by being acquired, based
on individual experiences, induced by a pathogen, antigen-specific and long lasting.
Adaptive immunity contains highly specialized cells (lymphocytes) able to recog-
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Figure 1.1.2: Nonspecific barriers as a first line of defense. Several natural barriers protect human body
from infection. These barriers are classified by their nature into mechanical, chemical and biological barriers. Skin
and membranes for example are from mechanical barriers in another hand stomach PH and antimicrobial peptides
secreted in tears, saliva, semen, respiratory tract and breast milk are considered as chemical factors. And commensal
flora serve as biological barriers.
nize the antigen, generate antibodies and activate cytotoxic cells, and induce the
long-lasting immunological memory.
In addition, the adaptive immune system needs several days to initiate antigen-
dependent processes (Figure 1.1.3). In contrast, the innate immunity has the ability
to react immediately when microbes are present, and provide signals necessary of
the development of the adaptive immune response to antigens. It is now widely ac-
cepted that antigen-specific immune responses may be achieved only if costimulatory
molecules and cytokines are provided together with antigen, and these molecules are
induced when the pathogen is first recognized by the cells of innate immune system
[77].
The mechanism generated following the recognition of dangerous signals, results
in the rapid mobilization of an inflammatory cascade. The components of innate
immunity can be divided to:
• Soluble molecules and membrane receptors
– Cytokines
– Complement proteins
– Antimicrobial peptides
• Cells (Table 1.1.1).
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Figure 1.1.3: General features of innate and adaptive immunity. Although there are many differences
between innate and adaptive immunity, they show high cooperation. Innate immunity reacts immediately and earlier
than adaptive immunity in response to pathogens and this nonspecific responses gives time to adaptive immunity
to prepare for specific responses. Innate immunity takes hours to eliminate pathogens but adaptive immunity
takes days. Innate immunity is antigen- independent in opposite of adaptive immunity (adapted from cellular and
molecular immunology 5 e. Abbas & Lichtman, 2005).
– Neutrophils
– Macrophages
– Dendritic Cells
– Natural killer (NK) Cells
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Cell type Neutrophil Macrophage Dendritic cell Natural killer cell
Phagocytosis Phagocytosis Antigen
presentation
Lysis of
viral-infected
cells
Reactive oxygen
and nitrogen
species
Inflammatory
mediators
Costimulator
signals
Interferon
Antimicrobial
peptides
Antigen
presentation
cytokines Macrophages
activation
Cytokines Cytokines interferon
Reactive oxygen
and nitrogen
species
Reactive oxygen
species
Complement
proteins
Table 1.1.1: Cellular components of innate immunity. Adapted from Kuby immunology, sixth
edition 2007.
1.2 Neutrophils
Phagocytes were discovered by Ilya Ilyich Mechinikov [102] and since then it was
believed that neutrophils are short lived cells with no programmed instructions [22].
Two decades ago this whole idea was changed when it was discovered that neutrophils
orchestrate complex arrays of adhesion-, chemoattractant-, and cytokine-driven sig-
nals and are able to synthesize cytokine in response to inflammatory stimuli [170].
Neutrophils are the first cells recruited and thus are an essential component of the
acute inflammatory response. Neutrophils are found circulating in the blood stream,
but they migrate out of the vasculature in response to inflammation or bacterial
attack; neutrophil migration is initiated as a result of process called chemotaxis. Pus,
which is hallmark of acute inflammation contains mainly neutrophils accounting for
its whitish/yellowish appearance.
Neutrophils are the most abundant white blood cells in humans accounting for
70%. The average half-life of a non-activated neutrophil in the circulation is about 4-
10 hours. Upon activation, neutrophils marginate, and undergo selectin dependent
capture followed by integrin dependent adhesion in most cases, after which they
migrate into tissues, where they survive for 1-2 days.
Neutrophils are phagocytes, internalizing and destroying microbes by the forma-
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tion of a phagosome into which reactive oxygen species ROS and hydrolytic enzymes
are secreted.
Neutrophils can also release an assortment of proteins in three types of granules
by a process called degranulation as well as extrude neutrophil extracellular traps
(NETs), a web of fibers composed of chromatin and serine proteases that trap and
kill microbes extracellularly. It is suggested that NETs provide a high local concen-
tration of antimicrobial components to bind, disarm, and kill microbes independent
of phagocytic uptake [24].
1.2.1 Granule Biogenesis and Granule Proteins
Neutrophil-derived microbicidal molecules are packed in granules that are re-
leased upon cell activation [90]. Granule biogenesis follows the granulocyte differen-
tiation pathway [21]. The azurophilic granules first emerge at the stage of promye-
locytes and contain myeloperoxidase, serine proteases, and antibiotic proteins [58].
Later in differentiation, at the metamyelocyte stage, specific granules contain-
ing lactoferrin and collagenase emerge, followed by the tertiary granule population
containing gelatinase, and a fourth type of granule, called the secretory vesicles,
appears at the stage of mature neutrophil [21].
Neutrophils use an array of antimicrobial peptides and proteins to destroy in-
vading microorganisms [90]. The azurophilic granules contain the majority of the
antimicrobial proteins that are released into the phagolysosome.
One of the most active participants in host defense against Gram-negative bac-
terial infections is bactericidal/permeability increasing protein (BPI), a 50 kDa pro-
tein stored in azurophil granules but also expressed at the plasma membrane of
neutrophils [49].
Another important group of antimicrobial peptides is the group of beta-sheet
defensins that comprises four members: human neutrophils peptides HNP1 to HNP4
[65]. Specific compounds also have these antimicrobial molecules which destined for
extracellular release, among them is hCAP-18 one of the cathelicidins.In neutrophils,
they are stored in specific granules in an inactive form [149].
Neutrophil-derived proteases are packed in azurophil granules and have the abil-
ity to degrade the majority of extracellular matrix components; as a result, they
play fundamental roles in physiological processes [123]. Serine proteases are a large
family of enzymes characterized by their active site, the so-called “catalytic triad”
composed of histidine, aspartic acid, and serine.
13
Introduction
The group of the neutral serine protease homologs stored in the azurophilic
granules of the neutrophil includes cathepsin G, elastase, proteinase 3, and the
enzymatically inactive azurocidin or CAP-37 [109], which are cationic glycoproteins
of similar size (25–29 kD).
Among purified neutrophil-derived proteases, cathepsin G [140], PR3, and azuro-
cidin [30] appear to have significant in vitro antimicrobial potential independent of
their enzymatic action.
Their antimicrobial activity is widely distributed because they are active against
Gram-positive, -negative bacteria, and fungi. Although in vitro studies did not
reveal antimicrobial activity of elastase, knock-out elastase mice show an impaired
host defense against Gram-negative bacterial sepsis [18].
Neutrophils contain metalloproteinases such as collagenase (MMP-8), which
specifically cleaves type I collagen, and (MMP-9), which degrades native type V
collagen. In addition, neutrophil metalloproteinases have been involved in the mod-
ulation of neutrophil functions such as the shedding of Fcg receptor [105].
Further regulation of the activity of metalloproteinases in the extracellular milieu
is achieved by specific inhibitors tissue inhibitors of metalloproteases have been
characterized (TIMP1, TIMP2 and TIMP3) [110] interacting with the activated
enzymes.
1.2.2 Oxidative molecules of neutrophils
The antimicrobial efficiency of human neutrophils depends on two coincident
events occurring in the nascent phagolysosome of stimulated neutrophils: the gen-
eration of ROS by assembly and activation of the NADPH-dependent oxidase and
the release of enzymatic or antimicrobial protein content in the granules.
These responses are triggered by numerous agonists promoting adhesion or by
phagocytic targets (Figure 1.2.1).
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Figure 1.2.1: Neutrophil effector systems are mobilized following phagocytosis. Complement opsonins
C3b and C4b are recognized by CR1 and CR3. IgG opsonins are recognized via the immunoglobulin receptors (FcgR).
The first microbicidal pathway is the oxidative reponse, which consists of the production of radical oxygen species
following NADPH-oxidase complex activation, including superoxide anion (O2-), hydrogen peroxide (H2O2), and,
via myeloperoxidase, hypochlorous acid (HOCl) and chloramines. The second microbicidal pathway is non-oxygen–
dependent and consists of the release in the phagolysosome or in the extracellular medium of preformed proteins
stored in granules. Serine proteases, antibiotic proteins, as well as myeloperoxidase are contained in azurophilic
granules. Metalloproteinases (collagenase and gelatinase) and antimicrobial proteins (lactoferrin and cathelicidin)
are contained in specific granules. Gelatinase is also contained in tertiary granules, also called gelatinase granules.
(Adapted from Witko-Sarsat and Descamps-Latscha, 1994.)
The activation of the oxidative metabolism, known as the respiratory burst, first
involves NADPH oxidase, an enzymatic complex composed of cytosolic (p40phox,
p47phox, and p67phox) and membrane proteins (p22phox and gp91phox), which
constitute a heterodimeric flavohemoprotein known as cytochrome b558 [7].
Two low-molecular weight guanine nucleotide-binding proteins are involved: Rac2,
which is located in the cytoplasm in a dimeric complex with RhoGDI (Guanine nu-
cleotide Dissociation Inhibitor), and Rap1A, which is located in membranes.
Upon activation of neutrophils, p47phox becomes phosphorylated and cytosolic
components migrate to the plasma membrane where they associate with cytochrome
b558 to assemble the active oxidase. This enzymatic complex is thus able to generate
superoxide anion (O−2 ), which can dismutate into H2O2 [115].
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There are three intermediates in the reduction of O2 to H2O2, namely O−2 , H2O2,
and the hydroxyl radical (OH•), which are formed by successive one electron addi-
tions. Despite numerous studies, the formation of OH• in phagocytes is still contro-
versial [25]. The formation of singlet oxygen appears to be an important event in
the microbicidal potential of neutrophils.
The generation of superoxide anion via the activation of NADPH oxidase is the
starting material for the production of a vast assortment of reactive oxidants, includ-
ing halogenated oxidants generated through the myeloperoxidase (MPO) pathway
(Figure1.2.2) [84]. MPO is a heme protein present in azurophil granules of neu-
trophils and monocytes, which is released upon cell activation into the phagolyso-
some or into the extracellular space.
MPO amplifies the toxic potential of H2O2 by producing reactive intermediates.
At plasma concentrations of chloride ion, the major product of MPO is hypochlor-
ous acid (HOCl). This potent oxidant chlorinates electron-rich substrates and ox-
idatively bleaches heme proteins and nucleotides[135].
MPO has a wide range of substrates leading to a wide variety of products. Amino
acids, especially taurine, can be chlorinated to yield chloramines, the so-called long-
lived oxidants. Interestingly, MPO can utilize nitrite and hydrogen peroxide as
substrate to catalyze tyrosine nitration in proteins [135].
MPO-derived oxidants have also been implicated in other processes unrelated
to host defense, including carcinogenesis [94], atherosclerosis, and chronic renal
failure[169].
NO-synthases are unique among eukaryotic enzymes in being dimeric, calmodulin-
dependent or calmodulin-containing cytochrome P450-like hemoproteins that com-
bine reductase and oxygenase catalytic domains in one monomer.
Reactive nitrogen intermediates include nitric oxide (NO), which can react with
oxygen to form much stronger oxidants such as nitrogen dioxide (NO2). The direct
toxicity of NO is modest, but is greatly enhanced by reacting with superoxide to
form peroxynitrite (ONOO−) (Figure1.2.2 ) [17].
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Figure 1.2.2: The generation of RNS and ROS via the activation of NADPH oxidase.
1.2.3 Neutrophil functions
1.2.3.1. Signaling, transepithelial migration and diapedesis toward
inflammatory stimuli
Neutrophils display multiple structurally related receptors for chemoattractants
that can trigger adhesion and direct cell migration and promote degranulation and
oxidative responses. These G-protein-coupled seven transmembrane glycoproteins,
also called “serpentines,” include receptors for complement C5a, formylpeptides,
PAF, leukotriene B4 [175], and receptors for C-X-C [131]. Ligation of chemoat-
tractants to such receptors activates phospholipases via heterodimeric G proteins,
resulting in intracellular Ca2+ release, Ca2+ channel opening and activation of con-
ventional protein kinase C isoforms [131].
Tyrosine kinases and the GTP-binding protein Ras are also activated. Ras ac-
tivation triggers the MAPK/ERK cascade, which appears to be involved in vari-
ous chemo attractant-induced neutrophil functions [88]. Activation of small GTP-
binding proteins of the Ras, Rac, and Rho families regulate actin-dependent pro-
cesses such as membrane ruffling, formation of filopodia and stress fibers, mediating
cell adhesion and motility [19].
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The chemoattractant receptors, via their coupled G-protein heterodimers, acti-
vate PI3-Kinase, which is involved in the pathways leading to degranulation and
NADPH-oxidase activation [156]. In many inflammatory diseases (gastrointestinal,
respiratory, urinary) neutrophils finally transmigrate across a polarized epithelium
to accumulate within a lumen [125].
Figure 1.2.3: Neutrophils adhesion and transmigration to site of inflammation. Innate immune
defence of neutrophils, in response to local infection or injury, neutrophils attach to the activated endothelium via
a series of interactions among adhesion molecules and their corresponding receptors. Attachment in combination
with locally secreted chemokines direct neutrophil migration to the site of infection or inflammation, where they
become activated and execute a cascade of defence mechanisms to protect the host against infections. Finally,
neutrophils commit apoptosis, resulting in phagocytosis by macrophages and subsequent resolution of inflammation.
Abbreviations: CAM-1, cellular adhesion molecule1; AMP, antimicrobial peptide.
Neutrophil transepithelial migration is mediated by b2 integrin CD11b/CD18
interaction with unknown epithelial ligand(s) distinct from ICAM-1, which might
include members of the proteoglycan family [125].
The rolling step is mediated by neutrophil L-selectin and by E- and P-selectins
18
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newly expressed on inflamed endothelial cells, (Figure 1.2.3), P-selectin, readily
mobilized in a few minutes to the endothelial cell surface following stimulation by
thrombin, histamine, or oxygen radicals, interacts primarily with a mucin-like ligand
PSGL-1 (P-selectin glycoprotein ligand-1), located at the tip of leucocyte microvilli
[107].
During the initial rolling on endothelial cells, integrin “activation” signals are
given by chemoattractants displayed on the endothelial membrane and presumably
also by the engagement of selectins and their counter-receptors (Figure 1.2.3).
Neutrophils integrate these signals of integrin engagement and those delivered
simultaneously by inflammatory cytokines or chemoattractants to activate a cascade
of intracellular events resulting in cell spreading, locomotion, degranulation, and
oxidative burst. These outside-in transduction pathways include the activation of
various tyrosine kinases [96].
Integrins behave as promiscuous transducers mediating signals triggered by these
GPI-linked receptors [126]. FcgRIIIb interaction with CD11bCD18 promotes anti-
body dependent phagocytosis [159], while CD14 interaction with CD11bCD18 only
occurs in the presence of LPS and LPS-binding protein and may play a role in the
generation of proinflammatory mediators [182].
Neutrophils migrate in tissues by haptotaxis. In particular, signals delivered by
“end target-derived” chemoattractants-such as formyl peptides, released by bacteria
or by mitochondria from dying cells, or complement C5a, produced in their imme-
diate surrounding-are dominant and override “regulatory cell-derived” attractants,
such as bioactive peptides (LTB4) or chemokines (IL-8) (Figure 1.2.4) [59].
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Figure 1.2.4: The chemotactic migration of neutrophils towards an inflammation site. Neutrophils
move through the endothelium and within tissues by responding to successive combinations of chemoattractant
gradients. Chemoattractants are released by endothelial cells, by activated stromal cells (macrophages, epithelial
cells. . . ), and by the inflammatory targets, ie, bacteria or dying cells. The direction of neutrophil movement is first
guided by the steepest local chemoattractant gradient and is then regulated by successive receptor desensitization
and attraction by secondary distant agonists. Finally, end-target attractants are dominant over regulatory cell-
derived agonists (adapted from Foxman et al, 1999).
1.2.3.2. Phagocytosis, degranulation, and bacterial killing
Neutrophil phagocytosis involves two different receptor classes (Figure1.2.1 ), Fcg
receptors-FcgRIIA (CD32), and FcgRIIIB (CD16) - as well as complement recep-
tors CR1 (CD35) and CR3 (or CD11b/CD18 integrin). Among these, the functional
phagocytic receptors are FcgRII and CR3, while CR1 and FcgRIIIB appear mostly
as co-receptors facilitating the function of the former receptors. Signaling path-
ways triggered by these two classes of receptors are different, as are the phagocytic
processes themselves.
The ingestion of IgG-coated targets is promoted by the aggregation of FcgRII
receptors and the phosphorylation of their cytoplasmic ITAMS (immunoreceptor
20
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tyrosine-based activation motifs) via the activation of Src-tyrosine kinases [40].
Phosphorylated ITAMS indeed serve as docking sites for SH2 domains of Syk tyro-
sine kinase, which triggers various pathways involving the activation of PI3-kinase
and of Rho proteins [101].
RhoA appears to be involved in the early F-actin recruitment and phagocytic cup
formation, but may not be absolutely required for FcR-mediated phagocytosis [32].
PI3-kinase is indeed involved in the myosin-induced “purse-string-like” contraction
of pseudopods that closes phagosomes [153]. CDC42 would regulate the extension
of membrane over the particle edges, and Rac1, together with PI3-kinase, would
allow membrane fusion and the final closure of the phagocytic cup [101].
Phagocytosis of C3bi-opsonized targets by complement receptor 3 (CR3) involves
a different process: complement-opsonized targets sink into the cell, which produces
little protrusions. CR3-mediated phagocytosis has been shown, in macrophages, to
involve Rho but neither Rac nor Cdc42 [32]. Adhesion of neutrophil CR1 and CR3 to
particles exclusively coated with C3b/iC3b is not sufficient to promote phagocytosis,
unless neutrophils are activated by PMA or by formyl-peptides and a contact with
fibronectin or laminin [171].
These stimuli result in the phosphorylation of CR1 and trigger the “inside-out”
signaling that activates CR3 binding capacity. Cooperativity between Fcg- and
complement-receptors occurs when C3b/iC3b-bearing targets are also opsonized by
antibodies or display glycosylated CR3 ligands [48].
Cross-talks between phagocytic receptors are suggested by the observation that
neutrophils from CR3-deficient (CD18-deficient) patients display an impaired anti-
body dependent phagocytosis [42]. And that FcgRIIIB interacts in cis with CR3,
via a lectin carbohydrate interaction [159]. Complex signaling pathways promoted
by the engulfment of opsonized targets lead to the fusion of protease-rich granules
with the phagosome and the triggering of the oxydative burst.
1.2.3.3. Cytokine synthesis
Human neutrophils are both a target and a source of various proinflammatory
cytokines, chemokines, and growth factors. Neutrophils are targets of proinflamma-
tory cytokines (IL-1 and TNF-a), chemokines (IL-8) and growth factors (granulocyte
colony stimulating factor G-CSF and granulocyte monocyte colony stimulating fac-
tor GMCSF). Indeed, these cytokines have been shown to amplify several functions
of neutrophils, including their capacity to adhere to endothelial cells and to produce
ROS.
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Neutrophils were previously considered to be devoid of transcriptional activ-
ity and capable of performing no or little protein synthesis. However, convincing
molecular evidence has now shown that neutrophils can synthesize and release a
wide range of cytokines and growth factors either constitutively or in an inducible
manner (Table 1.2.1). Though neutrophils produce many types of cytokines, this
production remains much lower than that produced by monocytes [33]. The pro-
duction of cytokines is also largely influenced by the stimulating agents and among
these, cytokines and bacterial endotoxins (LPS) are the most potent inducers.
TNF-a was originally described as a product of activated monocytes and macro-
phages displaying tumoricidal activity. It is a highly pleiotropic cytokine belonging
to the superfamily of membrane-anchored and soluble cytokines that are notably
involved in T cell-mediated immunity. Although it inhibits the growth of tumor
cells, it has an enhancing effect on the proliferation of certain normal cells and has
a great variety of nontumoral target cells, such as other white blood cells.
Cytokines that are Expressed by Neutrophils In Vitro
TNF-α Vascular endothelial growth factor (VEGF)
IL-1-α, IL-1-β Hepatocyte growth factor (HGF)
IL-12 Macrophage-CSF (M-CSF), IL-3, GRO-β
IL-1 receptor antagonist (IL-1Ra) IL-18 (IFN-γ inducible factor)
IL-8 TGF-α
Growth-related gene product-α (GRO-α) Oncostatin (OSM) and neurotrophins
Macrophage infiltrating protein-1α (MIP-1α), MIP-1β Secretion still debated:
Cytokine-induced chemoattractants (CINC) IL-6, monocyte chemotactic protein-1 (MCP-1),
Interferon-α (IFN-α), IFN-β granulocyte-macrophage CSF (GM-CSF), stem cell
Granulocyte colony-stimulating factor (G-CSF) factor (SCF), and IFN-γ
Fas ligand (FasL), CD30 ligand (CD30L)
Cytokines that are not Expressed by Neutrophils In Vitro
IL-10 MCP-2
IL-13 MCP-3
Table 1.2.1: Cytokine Expression by Neutrophils In Vitro. Adapted from Cassatella, 1999
TNF-a is involved in septic shock, cachexia, autoimmunity, and inflammatory
diseases. Its potent proinflammatory effects mainly result from its capacity to in-
crease expression of endothelial cell adhesion molecules and subsequently promote
neutrophil adherence to vascular endothelium. Finally, TNF-a is also a priming
agent for neutrophils that notably increases their phagocytosis, degranulation, and
oxidative responses. However, activated neutrophils have been shown to have the
capacity to express TNF-a mRNA [93].
Using GM-CSF as a stimulus, no secretion of the related TNF protein was de-
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tected. Soon after, the dual observation of expression of TNF-a mRNA and protein
secretion was reported with LPS as a stimulating agent. This observation was sub-
stantiated by other reports showing that Candida albicans also induces a potent
extracellular release of TNF-a [99].
Neutrophils express the mRNA of both IL-1a and IL-1β and release the related
IL-1 proteins. The stimuli listed in (Table 1.2.2) are in general all capable of in-
ducing IL-1 production by neutrophils. Some of these cytokine stimuli such as
IL-1β and TNF-a appear to induce IL-1 production by neutrophils. Interestingly,
anti-neutrophil cytoplasm autoantibodies (ANCA) have been shown to induce IL-1β
mRNA expression in neutrophils.
Agents able to trigger cytokine production by neutrophils
Cytokines and growth factors ANCA
TNF-a, IL-1a, IL-1β Matrix protein (fibronectin, laminin)
IL-4, IL-13, IL-10 Bacteria and related products
GM-CSF LPS
TGF-β Staphylococcus aureus
Chemoattractants Yersinia enterocolitica
fMLP Listeria monocytogenes
Surface molecule Fungi and related products
Anti-CD32 (FcgRII) and anti-CD16 (FcgRIII) antibodies Candida
Particulate agents Saccharomyces cerevisiae
Calcium microcrystals Zymosan
Urate microcrystals Protozoa
Other agents Plasmodium falciparum
Calcium ionophores Viruses
PMA, Concanavalin A Epstein-Barr virus
Table 1.2.2: Agents induces cytokines production from neutrophils. Adapted from Cassatella, 1999
IL-1 is usually released in concert with TNF-a and exerts similar effects on neu-
trophils (see above). Two classes of IL-1 receptors (IL-1RI and IL-1RII) expressed
on a wide variety of cells have been described. IL-1Ra is a 23- to 25-kDa protein
made by the same cells as those that produce IL-1. It exerts its inhibitory action
on IL-1 by binding to IL-1 receptors without triggering any signal transduction or
biological activity.
The expression of IL-1Ra mRNA in LPS-treated neutrophils appears to be
greater than that of LPS-treated monocytes and an almost 100-fold excess of IL-1Ra
over IL-1 is usually produced by activated neutrophils. It has thus become evident
that neutrophil-derived IL-1Ra could contribute to modulate the IL-1 induced in-
flammatory and immune responses.
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Chemokines are usually classified as C-X-C or C-C chemokines on the basis of
the position of the first two cysteine residues, and IL-8 is a prototype of the C-
X-C family. IL-8 was first described as a potent neutrophil chemoattractant and
activator [8] and is expressed in response to LPS. IL-8 is secreted by a variety of
cells including T lymphocytes, epithelial cells, keratinocytes, fibroblasts, endothelial
cells, and neutrophils. Interestingly, IL-8 is the most abundantly secreted cytokine
by neutrophils, and neutrophils are the primary cellular target of IL-8 [62].
Concerning other cytokine producing cells, cytokine expression by neutrophils
can easily be modulated by the T-cell– derived regulatory cytokines, i.e., positively
by Th1 type cytokines such as IFN-g, and negatively by Th2 type cytokines such as
IL-10, IL-4, and IL-13, Given the pathophysiological importance of such regulatory
pathways [34].
1.2.3.4. Apoptosis and the resolution of acute inflammation
Most acute inflammatory responses resolve spontaneously due to endogenous
“stop programs” that switch off inflammation and limit destruction of host tissues.
These include the elimination of infectious agents by phagocytosis, the progressive
decrease of leucocyte recruitment promoted by endogenous “braking signals,” and
finally, the apoptosis and clearance of leukocytes [92].
Neutrophil apoptosis and subsequent ingestion by macrophages is the major
mechanism for clearing neutrophils that have been recruited to the inflamed sites and
thus for resolving inflammation. The constitutive apoptosis of senescent neutrophils
involves proteolytic cascades-caspases, calpains, and the proteasome-that activate
kinases, e.g., caspase 3-mediated activation of protein kinase C-d [130].
Inflammatory mediators, such as LPS or GM-CSF, delay the apoptosis of neu-
trophils by increasing mitochondrial stability and reducing caspase 3 activity [168],
and by down-regulating the gene expression of Bax, a pro-apoptotic member of the
Bcl-2 family [46].
Macrophages can trigger neutrophil apoptosis by expressing cell surface Fas lig-
and (FasL) and releasing soluble FasL that reacts with the Fas “death receptor”
on neutrophils. Ingestion of opsonized particles or of apoptotic neutrophils indeed
promotes the release of soluble FasL by macrophages and the killing of bystander
neutrophils [28]. This may represent a negative feedback loop accelerating the reso-
lution of inflammation by eliminating recruited leukocytes by apoptosis. This active
suppression of inflammatory mediator production is presumably an important step
in the resolution of inflammation.
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1.2.4 Neutrophils in diseases
Tissue damage after acute bacterial infection is partly due to excessive neutrophil
infiltration and activation in the infected tissue [155]. Two inherited defects affect
neutrophil granule structure [98]. The first is the specific granule deficiency, which
is a rare congenital disorder marked by frequent and severe bacterial infections.
In this disorder, neutrophils are characterized by a lack of specific granules and
defensins, abnormalities in neutrophil migration, and impaired bactericidal activity.
The second inherited granule deficiency is the Chediak-Higashi syndrome (CHS),
which is a rare autosomal recessive disorder associated with an immune deficiency
leading to increased susceptibility to infection and a life-threatening lymphoma-like
syndrome. In CHS a lack of natural killer cell function and a neutropenia may be
found, with a prominent defect in formation of neutrophil granules [113].
Cystic fibrosis is a hereditary disorder caused by mutations of the cystic fibrosis
transmembrane conductance regulator (CFTR), the product of which is a membrane
protein thought to function as a chloride channel. The lethal clinical manifestations
are clearly related to the thick, infected mucous and chronic neutrophil-dominated
airway inflammation [47]. Neutrophils are considered responsible for the early onset
and the promotion of the inflammatory process in CF, which starts within the first
year of a CF patient’s life [6]. Regarding neutrophil functions, myeloperoxidase
dependent oxygenation activities appear to be significantly higher not only in CF
homozygotes, but also in heterozygote parents of CF patients [132].
1.3 Antimicrobial peptides (AMPs)
Innate immune system does not only recognize pathogens, but also inactivates
them using antimicrobial peptides (AMPs) and proteins. The natural ability of
normal tissues to possess antibacterial activity has been revealed in 1922 by Flem-
ing, who has isolated the first tissue-derived bacteriolytic substance (now known as
lysozyme) [57]. Nowadays there about 900 different AMPs and proteins have been
described [27].
Antimicrobial proteins are present at relatively high concentrations in host de-
fense cells of myeloid origin, especially neutrophils, but also in epithelial cells (ECs)
and tissue secretions. Some of them (like lysozyme, secretory phospholipase A2 or
cathepsin G) are enzymes that lyse various microbial components. For example,
lysozyme, which is produced by phagocytes and ECs, degrades bacterial PGNs by
cleaving the glycosidic bond of N-acetyl glucosamine [56].
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Other antimicrobial proteins use nonenzymatic strategies. For example lactofer-
rin, a highly abundant component of milk and mucosal secretions, binds to iron, an
essential survival factor for many microbes, and also possesses bactericidal activity
at the N-terminus [63].
Another example is the bactericidal/permeability-increasing protein (BPI) selec-
tively exerts multiple activities against gram-negative bacteria: cationic N-terminal
peptide causes direct cytotoxicity and neutralizes LPS, while C-terminal domain
binds to phagocytes and, therefore, may act as an opsonin [50].
AMPs are endogenous polypeptides of fewer than 100 amino acids. They have
antimicrobial activity at physiological concentrations under conditions prevailing in
the tissues of origin or elevating there during pathologic conditions [64]. Unlike
the commonly called antibiotics, which are in most cases synthesized by special
metabolic pathways, the amino acid sequence of AMPs is naturally encoded in the
genetic material of the host organism [27].
There are many different groups of AMPs, however the most active group is the
cationic amphipathic peptides, which are able to accumulate and interact with and
subsequently damage negatively charged microbial membranes [183].
In addition, some AMPs can alter bacterial metabolic pathways, reduce cell-
wall, nucleic acid, and protein synthesis, and inhibit enzymatic activity [27]. In
humans and other mammals, defensins and cathelicidins constitute the two main
AMP families [174]. Neutrophils and epithelial cells (ECs) are the major sources of
mammalian AMPs [183].
1.3.1 Defensins
Defensins are cysteine-rich, cationic peptides with b-sheet structures that are
stabilized by three intramolecular disulphide bonds between the cysteine residues.
Mammalian defensins are classified into three subfamilies, a-, b- and j-defensins,
which differ in their distribution of and disulphide links [64]. Human a-defensin-1,
-2, -3 and -4 are mainly expressed by neutrophils and, for this reason, are also called
human neutrophil peptides (HNPs) [66].
hBD-1 is constitutively expressed, whereas hBD2 and hBD3 can be induced by
microbes or inflammatory cytokines [64]. Defensins are small cationic, antibiotic
peptides that contain six cysteines in disulfide linkage. They are active against
Gram-positive and Gram-negative bacteria and act by inducing microbial membrane
permeabilization. They also appear to regulate the inflammatory process through
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binding to protease inhibitors such as a 1-antitrypsin and a1-antichymotrypsin [124]
1.3.2 Cathelicidins
Cathelicidin family contain an N-terminal signal peptide (preregion), a conserved
cathelin-like domain (proregion), and a C-terminal microbicidal domain (hence the
name “cathelicidin”) (Figure 1.3.1) [180]. Humans generate only one cathelicidin,
called LL-37 [89].
Figure 1.3.1: Basic structure of cathelcidins LL-37/hCAP18 for human and CRAMP mice. Humans
and mice each express a single cathelicidin, which are encoded by similar genes and have similar alpha-helical
structures, spectra of antimicrobial activity. Cathelicidin is synthesized as an inactive precursor protein with an
amino-terminal signal sequence, a central cathelin domain, and an inactive carboxy-terminal antimicrobial peptide
(AMP) domain. Serine proteases, including stratum corneum tryptic enzyme (SCTE), cleave the AMP domain to
generate the active antimicrobial peptide.
They are usually stored in the granules of neutrophils as an inactive form and
undergo processing to mature peptide during or after secretion by appropriate pro-
teases.
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For example, hCAP18 is cleaved by proteinase 3 [150] or elastase [69] to liberate
its C-terminal antimicrobial domain, which is called “LL-37” because this peptide
begins with two leucine residues and has 37 amino acid residues. hCAP18/LL-37
has also been found in various epithelia [11].
Because neutrophil secondary granules readily degranulate to the extracellular
space, cathelicidins can be found in inflammatory fluids at relatively high concen-
trations [36]. Moreover, accumulation of neutrophils within mucosal tissues may
activate epithelial cathelicidin by a proteolytic process mentioned above.
The C-terminal AMPs of cathelicidins are microbicidal against a broad spectrum
of microorganisms, including bacteria, fungi, and parasites [183].
Similar to other cationic AMPs, the mechanism of cathelicidin-mediated micro-
bial killing depends on the formation of ion channels or pores in the microbial cell
membrane. LL-37 also possesses a potent endotoxin-neutralizing activity due to
interaction with a negatively charged lipid A portion of the LPS molecule [89].
There is evidence for other host defense and immunoregulatory functions of
AMPs. It has been shown that some of the AMP’s may act as chemoattractants for
inflammatory and immune cells. LL37 attracts neutrophils, monocytes and T cells
via formyl-peptide receptor-like 1 (FPRL1), eosinophils via formyl-peptide receptor
(FPR). AMPs may also be involved in tissue homeostasis: HNPs have been shown
to increase airway epithelial repair [1], LL-37 can induce angiogenesis [88].
Recent data suggest that some AMPs may play a regulatory role during inflam-
mation [106].
1.4 Inflammation as a host defense response
Inflammation is a tissue response to infection, injury or irritation. The principal
features of inflammation are (1) the presence of damage as a trigger of host response;
(2) activation of host defense and immune mechanisms; and (3) healing of damaged
tissues [114].
Inflammation starts with tissue injury [102] (Figure 1.4.1).
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Figure 1.4.1: Inflammatory process. Inflammation is initiated by tissue injury, caused by physical damage
to the tissue barrier or infection. Various mediators (including chemokines and vasoactive amines) are released by
tissue cells (epithelial cells and mast cells) to increase vascular permeability and attract inflammatory cells from
blood (neutrophils, monocytes or eosinophils), that migrate to the site of injury and kill microbes. Dendritic cells,
matured in the presence of pathogens, migrate into regional lymph node, where they present antigen to T cells and
thereby prime specific immune response.
Injury can be recognized at all levels of biological organization [74]. Following
injury, tissue cells release mediators with different defense functions; AMPs to kill
microbes immediately; vasoactive substances (for example, histamine of mast cells)
to increase the local blood flow and vascular permeability, and cytokines to attract
and activate inflammatory cells of hematopoietic origin. For example, IL-8 is a
major chemoattractant for neutrophils; GM-CSF increases survival of granulocytes;
TNF-a activates virtually all cells involved in inflammatory process [151].
Leukocyte migration into damaged tissue is an essential feature of inflamma-
tion. Neutrophils (also called polymorphonuclear /PMN/ leukocytes) are the most
abundant hematopoietic cells during the early stages of nonspecific inflammation
[114].
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Once neutrophils have migrated into the tissue, their primary role is to rec-
ognize, phagocyte and kill pathogens. Following binding to opsonized pathogens,
neutrophils extend pseudopods that engulf the particle and take them up into the
maturing phagosome [139].
Killing by neutrophils occurs intracellular by AMPs, like a-defensins [66], and
serine proteases, degranulate into phagosome, or reactive oxygen compounds gener-
ated upon activation of neutrophil membrane-bound NADPH oxidase enzyme com-
plex [139] or extracellularly through a release of the AMPs (like cathelicidins) of
specific granules [183]. At the end of their phagocytosis role they die and then are
removed and/or replaced by mononuclear inflammatory cells. Following migration
into tissues, monocytes can differentiate to become macrophages or DCs[5]. Being
localized in tissues, these cells play a key role in inflammation as sensors of danger,
initiators and regulators of host defense responses. They express particularly high
levels of PRRs [78].
Phagocytosis of microbes is a fundamental function of macrophages, discovered
by Mechnikov more than 100 years ago [102]. Immature DCs are also potent phago-
cytes [14]. An important consequence of phagocytosis by macrophages and, espe-
cially, DCs is processing the antigens for presentation on major histocompatibility
complex (MHC) molecules to T cells, providing a link between inflammation and
immunity (innate immunity and adaptive immunity) [20].
Conversion of the host defense response from antimicrobial tissue-damaging pro-
cesses to the anti-inflammatory processes is necessary to promote tissue repair at
the late stages of inflammatory reaction [114]. During the progression of inflam-
mation, platelet-leukocyte interactions elicit the formation of lipoxins A4 and B4,
which serve as “stop signals” by blocking the further recruitment of PMNs from the
circulation [137].
Following phagocytosis of apoptotic cells generated in inflamed tissue, macrophages
produce TGF-b, a potent anti-inflammatory cytokine [74]. On the other hand, pro-
longed and excessive local inflammation is associated development of chronic au-
toimmune diseases, tissue injury[108], pathologic angiogenesis, fibrosis and cancer
[9].
1.5 Lung immunity and airway epithelium
The lung, like the skin and the gut, has a large surface area that is constantly
exposed to the environment and is also a metabolically active organ with a large
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blood-air interface designed for both gas exchange and capillary endothelial cell
processing of a myriad of endogenous substances.
This dual function of gas exchange and metabolism can only be maintained
throughout adult life if the structure of the organ is homeostatically maintained
and defended against the external and internal environment. A program of lung
structure maintenance has a critical importance during lung development. Later in
life, elements of this developmental program are utilized to protect the lung against
destruction, antioxidants, antiproteases, and attack by the innate immune system.
Airway epithelium represents a barrier not like any other barriers in the body.
First, it serves as a mechanical and chemical filter of the inhaled air, providing
sterility and safety of the alveolar compartment of the lung. The gas exchange
process in alveoli requires the ventilation of a large volume of environmental air that
potentially contains pathogens and dangerous particles. The latter must be captured
and neutralized in the airways; otherwise, pulmonary infection will develop.
Second, intact airway epithelium is a primary regulator of the mucosal home-
ostasis, preventing the access of pathogens to the subepithelial and submucosal
compartments that may result in excessive inflammation and / or generalized infec-
tion. Airway epithelium is covered on its apical surface by a thin liquid layer called
airway surface liquid (ASL) (Figure 1.5.1).
Figure 1.5.1: Airway epithelial barrier. represents a physical border of ECs that resists damage and prevents
pericellular diffusion of exogenous factors due to TJs which link the neighboring ECs at the apical zones. Defense
function is maintained by the mucociliary escalator and antimicrobial substances present in the ASL that consists
of mucus, produced by goblet cells and other secretory cells, and periciliary liquid layer (PCL). Intraepithelial DCs
and lymphocytes provide a local sentinel function and are involved in the regulation of tissue homeostasis.
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The ASL is the first line of defense against inhaled pathogens and is important
for effective mucociliary clearance [86]. Almost one century ago, Fleming observed
that respiratory secretions possess bactericidal properties [57]. The ASL consists of
two layers, a mucus layer and a periciliary liquid layer (PCL), that are propelled
upward by coordinated ciliary beating [23].
1.5.1 Airway antimicrobial proteins
Antimicrobial proteins and peptides (AMPs) represent a first-line innate effec-
tor mechanism to kill microbes directly due to interaction with their membranes or
disrupting their metabolic status as described earlier. In the airway mucosa, antimi-
crobial factors from submucosal gland cells, ECs and neutrophils are accumulated
within the ASL [163].
Among them, the proteins lysozyme, lactoferrin and SLPI are the most abundant
factors of airway secretions in health and in lung diseases such as asthma, chronic
bronchitis, and CF [26].
Surfactant proteins A and D arising from alveolar ECs bind bacteria and fungi,
as well as microbial factors, and enhance pathogen clearance [172].
Cationic AMPs of the defensin and cathelicidin families contribute considerably
to the lung defense [63]. The production of other AMPs increases dramatically
during infection and inflammation: for example, hBD2 can be induced via (TLR2)-
MyD88-NFkappaB pathway by microbial factors and inflammatory cytokines [75].
The levels of LL-37 increase mainly via activation resulting from proteolytic
cleavage of the mature peptide from inactive precursor hCAP18/LL-37 by proteinase
3 [150]or neutrophil elastase [69]. However, the exact mechanism of LL-37 activation
in the airway epithelium remains unknown.
Although transcriptional induction of LL-37 expression in the skin has been
reported [60], there is no data supporting the existence of a similar mechanism in
the lung ECs. The levels of LL-37 were found to be increased in the sputum [148]
and BALF [36] in CF lung disease, characterized by chronic neutrophil inflammation
and colonization of airways with P. aeruginosa. Thus, activation of the peptide by
proteases from neutrophils and bacteria is possible.
However, the major source of LL-37 in the airways is likely neutrophils recruited
in the lung during inflammation. AMPs have a broad spectrum of activity against
Gram-positive and Gram-negative bacteria as well as against fungi and enveloped
viruses [10].
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The minimal inhibitory concentrations of the peptides are in the range 0.1–100
mg/ml [10]. AMPs differ in their killing activity against particular pathogens: LL-37
is more potent than HNP1 against a variety of bacteria including P. aeruginosa [11],
and HBD-2 is more effective than HBD-1 in killing Escherichia coli [146].
Many AMPs work synergistically. Three factors found in human airways - lacto-
ferrin, SLPI and LL-37 - have synergistic activity with lysozyme [11].
The information about the activities of AMPs in the lung in vivo is limited.
Cathelicidins are the only AMPs extensively studied in vivo. It has been shown that
mice treated with intratracheal LL-37/hCAP-18 vector had a lower bacterial load
and a smaller inflammatory response than did untreated mice following pulmonary
challenge with P. aeruginosa [12].
CRAMP, a mouse analog of LL-37, protects mice against necrotic skin infection
caused by Group A Streptococcus [118] and urinary tract E.coli infection [38].
The latter study provides evidence that EC-derived cathelicidin contributes sub-
stantially to mucosal protection from bacteria. Moreover, cathelicidin protects from
sepsis due to the binding to and neutralization of endotoxin [12, 39].
1.5.2 Clara cells
Clara cells are epithelial cells lining the pulmonary airways (Figure 1.5.2), which
are distinct from mucous and secretory cells in morphology and their secretory
products. Clara cells are non-ciliated, non-mucous secretory cells localized mostly
in the bronchiolar surface epithelium, and they are one of the most multifunctional
and heterogeneous cell types in the mammalian lung [100].
Clara cells are also the principal site of xenobiotic metabolism by the cytochrome
P450 mono-oxygenase system within the lung [127]. Studies have shown that naph-
thalene causes severe selective destruction to clara cells in the mouse [128].
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Figure 1.5.2: Respiratory bronchiole and clara cells. Alveolar ducts are small ducts leading from the
respiratory bronchioles to the alveolar sacs.The respiratory bronchiole epithelium consists of ciliated cuboidal cells
and clara cells.
Toxicity of the clara cells is due to the metabolism of naphthalene by cytochrome
P450 mono-oxygenase and a toxic intermediate that causes distal airway clara cell
swelling, vacuolization, and exfoliation into the lumen of the airways 24 h after
injury is initiated [164].
One of the major secretory products of human pulmonary clara cells is the 10-
kD protein (CC 10) [145]. This protein is a homodimer consisting of 70 amino acid
subunits connected by two disulfide bonds [144]. CC10 possesses varied biochemi-
cal and biological properties including phospholipase A2 (PLA2)-inhibitory activity
[143], its ability to bind methylsulfonyl polychlorinated biphenyls [120] and possess
also anti-inflammatory activity [31].
1.5.3 Pathogenesis of pulmonary emphysema
Emphysema comes from the Greek word that means "inflation". It is a pathologic
condition of the lung which is defined as airspace enlargement of the adult lung [147].
It is often caused by exposure to toxic chemicals, including long-term exposure to
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smoke. Emphysema is characterized by loss of elasticity of the lung tissue, from
destruction of structures supporting the alveoli. Thus the small airways collapse
during exhalation, as alveolar collapsibility has increased. This impedes airflow and
traps air in the lungs.
Emphysema symptoms include shortness of breath on exertion and later at rest,
hyperventilation, and an expanded chest. There is no emphysema-specific treatment.
Mortality and morbidity from COPD (chronic obstructive pulmonary disease) is an
increasingly serious global health problem; COPD ranked sixth among the causes of
death globally in 1990 but is expected to be the third most common cause of death
in 2020 [35].
The destruction of alveolar-capillary (epithelial and endothelial) cells by pro-
teolytic enzymes has been generally accepted as one of the principle mechanisms
of destructive airspace enlargement based on the demonstration that intratracheal
instillation of the cysteine protease papain (a meat tenderizer) caused emphysema
in rats [68] and on an association between emphysema and a genetic deficiency in
the neutrophil elastase inhibitor a1-antitrypsin (AAT) [52].
The pathology of COPD relates to inflammatory changes in the small airways
and to the loss of alveolar septal structures and small vessels. The alveolar septae
are infiltrated by neutrophils, clusters of CD68+ macrophages, and lymphocytes.
Neutrophils elastase and MMP-12 released by activated macrophages enzymatically
destroy the elastin scaffold of the alveolar spaces. However, the production of pro-
teases is not restricted to inflammatory cells; structural cells such as epithelial and
endothelial cells are also capable of producing proteases [104].
Elastin fragments in turn are chemotactic [76] and attract inflammatory cells
to sites of injury, thus suggesting a joint role of inflammatory cells and proteases.
Strong experimental support of this concept is provided by data showing that elim-
ination of alveolar macrophages in rats [122] and knockout of MMP-12 in mice [71]
protects these animals against cigarette smoke–induced emphysema.
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2 Hypotheses and goals
The aim of the present study was to analyze the effect of cathelicidin on the in-
teraction between neutrophils and microbial patterns. Stimulation experiments were
used applying various microbial stimuli and characterized the effect of cathelicidin.
Also the production of ROS was determined. Further, the role of endogenous cathe-
licidin were determined by using neutrophils isolated from CRAMP deficient mice.
The role of cathelicidin as endogenous (physiological form) and exogenous (treat-
ment form) presence in modulating some immunological functions of neutrophils
(cytokines release, ROS release, phagocytosis and bactericidal activities) , enhanc-
ing airway epithelia regeneration and reducing induction of pulmonary emphysema
in mice are essential findings of this work. In this project the following hypotheses
were tested:
1. Whether cathelicidin LL-37 modulates inflammatory reaction of human neu-
trophils in response to LPS and whole bacteria. Although it is known that
LL-37 neutralizes endotoxin [89] and modulates activation of macrophages and
monocytes by LPS [106], the data regarding neutrophils are limited [185].
2. Whether mouse endogenous cathelicidin antimicrobial peptide CRAMP, ex-
pressed by mouse neutrophil has a role in increasing neutrophils antimicrobial
activity.
3. Whether increasing of bactericidal of neutrophils in the presence of cathelicidin
related to the improvement of neutrophil phagocytosis..
4. If endogenous CRAMP secretion is sufficient to reduces an inflammatory re-
action of mouse neutrophils in response to bacterial stimulant. It has been
shown that LL-37 may prevent sepsis and be useful in lower doses for treating
sepsis in rats [61].
5. Whether the presence of cathelicidin can enhance airway repair after acute
lung injury, in addition to its direct bactericidal effect. There are published
data regarding defensins which can enhance and regulate airway repair [1].
6. Whether the presence of cathelicidin protects from the development of pul-
monary emphysema. No data currently exist in literature regarding this pos-
sibility.
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3 Materials and methods
3.1 Analysis of inflammatory innate immune reaction in re-
sponse to bacterial stimulants
In present work neutrophils were isolated either from human blood or mouse
peritoneal cavity and different methods and protocols were applied as described
below.
3.1.1 Isolation and preparing of murine neutrophils
CRAMP-deficient mice in a 129/SVJ background [118] and their wildtype con-
trols were used for neutrophil isolation. The animals were kept under specific
pathogen free conditions at the animal center of the University of Marburg. The ani-
mal experiments were approved by the responsible authorities (Regierungspräsidium
Giessen).
Mice were intraperitoneally injected with 1 ml of sterile 4% thioglycollate broth
(BD Difco, Heidelberg, Germany), the animals were euthanized after 4 hours and
the peritoneal cavity was lavaged twice with 10 ml of PBS (PAA, Cölbe, Germany).
The peritoneal lavage was centrifuged at 1200 rpm for 10min. and red blood
cells were lyzed by RBC lysis buffer (NH4Cl 4.14 g, KHCo3 0.5 g, EDTA 0,1 ml and
adjustment PH= 7.2-7.4 with Hcl 1N for 500 ml PBS)[95, 37].
After washing cells with PBS, the cells were resuspended in RPMI 1640 medium
(Gibco, Grand Island, NY). The purity of neutrophils was determined using cytospin
preparations stained with Giemsa.The peritoneal cell populations were consistently
composed of >97% neutrophils. Viability of the cells was tested using trypan blue
staining and was consistently >95%.
3.1.2 Isolation of human neutrophils
Buffy coats made from 500 ml blood of healthy volunteers donor were obtained
from the blood bank of the University hospital Marburg and diluted 1:1 with PBS
containing 2 mM of EDTA.
Human neutrophils were isolated using dextran sedimentation and Ficoll-Paque
gradient centrifugation protocol[176]. Blood 9 ml of diluted Buffy coat was layered
onto 15 ml of Ficoll 400 (Sigma-Aldrich, Schnelldorf, Germany), and centrifugated
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at 1500 rpm for 30 minute and stopped without braking.
The cell pellet, containing granulocytes and red blood cells was resuspended in
25 ml dextran 4% and incubated at room temperature for 40 min. The neutrophils
in the upper phase were collected and red blood cells lyzed with RBC lysis buffer
which contains (NH4Cl 4.14 g, KHCo3 0.5 g, EDTA 0,1 ml and adjustment PH=
7.2-7.4 with HCl 1N for 500 ml PBS).
Cells were washed two times with PBS and the pellets resuspended in RPMI
medium containing 0.1 % serum albumin. The neutrophils were counted, the pu-
rity of the cell preparation was determined by cytospin preparations and Giemsa
staining, and the viability was tested using Trypan blue staining. The purity and
viability of isolated neutrophils were more than 95%.
3.1.3 Preparation of bacteria
Staphylococcus aureus 113 wt (Dr. A. Peschel, University of Tubingen, Ger-
many) and Pseudomonas aeruginosa NH57388A and NH57388C (Dr. Niels Hoiby,
University of Copenhagen, Denmark) were used for stimulation experiments [11],
One day before experiment a loop from bacteria stock (-80 °C) is inoculated into
50ml Luria-Bertani (LB) broth (Roth, Karlsruhe, Germany) and incubated with
shaking overnight at 37 °C, then the next day the bacteria was streaked onto LB
agar plates , and the plate were incubated at 37 °C.
Colonies were harvested, suspended and washed three times in Dulbecco’s PBS
with Ca2+ and Mg2+. The number of bacteria in suspension was adjusted based
on measurements of the OD 600 nm and using a reference dilution. The medium
was replaced with PBS. Complement from heat- inactivated human serum (95°C for
1 h) was used to opsonize the bacteria (37 °C, 30 minute, 60%).
3.1.4 Neutrophil stimulation
The LL-37 peptide (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) and its scram-
bled form sLL-37 (RSLEGTDRFPFVRLKNSRKLEFKDIKGIKREQFVKIL), were chemically
synthesized (Charité, Humboldt-Universität, Berlin, Germany). Isolated neutrophils
were stimulated with bacteria as following, 104 CFU / ml bacteria were heat-
inactivated (95°C for 1 h) and opsonized with inactivated human serum (37 °C,
30 min., 60%) and incubated with human neutrophils (1 x 106 cell / ml).
The supernatants were collected after centrifugation at 1200 rpm for 10 min.
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For LPS stimulation, LPS 100 ng/ml (Sigma-Aldrich Chemie GmbH, Munich,
Germany) incubated with neutrophils suspensions were pre-incubated with different
concentrations of LL-37 (5, 10, 15, and 20 µg / ml) for 30 minutes and others
neutrophils were not pretreated with LL-37. After the time of incubation (12h) the
supernatants were collected and kept for futher detection in -20 °C.
3.1.5 Bacterial killing assay
Neutrophils were isolated from the peritoneal cavity of CRAMP-deficient and
their wildtype mice in a 129/SVJ background as described above. To analysis the
neutrophils’ antimicrobial activity, opsonized bacteria and mouse neutrophils (1 x
106 cell / ml) were incubated together in one 1.5 ml eppendorf tube at a ratio of 1:1
(shaking at 200 rpm, 37 °C). 20 µl aliquots were removed in deferent time points
incubation 0, 30, 60, and 90 min and neutrophils were lyzed by adding Triton 0.1
%. Dilutions in PBS were plated onto LB agar plates and bacterial colonies were
counted after 24 hrs of incubation in 37 °C.
The rate of dead bacteria was evaluated and used as a parameter to compare
between neutrophils isolated from WT and CRAMP-KO mice [91]. opsonization
was done by incubating the bacteria suspension with 60 % of inactive human serum
at 37 °C for 30 minutes.
The isolated neutrophils were resuspended in PBS-G-SA contains 5 mM glucose
and 0.1% serum albumin (Sigma-Aldrich, Schnelldorf, Germany) in order to reduce
the adherent affinity of neutrophils. The serum used in opsonization was inactivated
by heating 65 °C for 1h. The bacterial mediums were used are LB broth and LB
agar (Roth, Karlsruhe, Germany). Controls were performed by incubating bacteria
without neutrophils in the same medium and all condations.
3.1.6 Enzyme-linked immunosorbent assay (ELISA)
Cytokine levels in culture supernatants were determined using a commercially
available DuoSet ELISA Development kits for IL-1ß,IL-6, IL-8 and TNF-a according
to the manufacturer’s instructions (R&D Systems).
In brief, 96-well microplates were precovered with capture antibody and incu-
bated overnight. Then after washing and incubation with a blocking reagent, 100
ml per well of sample or standard were added and incubated overnight at 4 °C.
After washing and subsequent incubation with detection antibodies during 2 h
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and Streptavidin-POD Conjugate (Roche Diagnostics) during 20 min at room tem-
perature, 100 ml of TMB+Substrate-Chromogen (Dako Deutschland GmbH, Ham-
burg, Germany) was added. The reaction was stopped by adding 3N H2SO4, and
the absorbance was measured using ELISA reader at 450 nm or 490 nm.
3.1.7 Cytotoxicity assays
The cytotoxic effect of different concentrations of LL-37 (0.5-50 mg/ml) on iso-
lated neutrophils was assessed by colorimetric quantification of the lactate dehy-
drogenase (LDH) in cell supernatants using the Cytotoxicity Detection Kit (Roche
Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instruc-
tions. Briefly, after 24 h of stimulation, cell-free supernatant was collected and
incubated with the substrate mixture from the kit.
LDH activity was determined in a coupled enzymatic reaction, in which tetra-
zolium salt is reduced to formazan. The content of formazan dye was then quanti-
tated by measuring the absorbance at 490 nm using ELISA reader.
3.1.8 Western-blot
To test whether CRAMP was released from neutrophils during LPS stimulation,
western-blot analysis was performed to detect CRAMP release in supernatants .
After stimulation, samples were centrifugated 1200 rpm for 5 min. and the supper-
natants were separated and stored in -20 °C.
Supernatants were mixed with Roti-Load® loading buffer (Roth, Karlsruhe, Ger-
many) and separated on a 10 - 20% tris-tricine gel [136](Anamed, Darmstadt, Ger-
many) according to the manufaturers instructions. The seperated samples were
blotted on a nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA, USA)
using a tank-blotting system (Bio-Rad Laboratories, Hercules, CA, USA) at a con-
stant power of 20 W for 1.5 hours using a standard towbin-buffer system [162].
After transfer the membrane was blocked for one hour in a blocking solution
containing 5% poor fat dry milk (Sigma, Steinheim, Germany) and PBS. For au-
toradiographic detection a polyclonal CRAMP antibody (Pineda Antibody Service,
Berlin, Germany) and a horseradish peroxidase (HRP)-labeled secondary rabbit-IgG
antibody (GE-Healthcare, Little Chalfont UK)) were used.
The CRAMP antibody, raised against a synthetic CRAMP-Peptide (ISRLAG-
LLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE) (Dr. Peter Henklein, Charité Berlin ) was
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used in 500-fold dilution in 5% poor fat dry milk-PBS and incubated at 4 °C with
mild agitation overnight (Roth, Karlsruhe, Germany). After 3 washing steps with
PBS the species specific HRP-labeled secondary antibody was used in a 1000-fold
dilution in 5% poor fat dry milk-PBS and incubated with mild agitation for 1 hour
at room temperature.
After 3 final washing steps with PBS the peptides were detected using the Su-
perSignal® West Pico chemiluminsecent substrate (Pierce Biotechnology, Rockford,
USA) on Kodak scientific imaging films (Eastman Kodak Company, Rochester, N.Y.,
USA).
3.2 Detection of neutrophilic reactive oxygen species ( ROS)
production
To measure cellular productions of reactive oxygen species in present measure-
ment, luminometry and fluorometry methods were used because of their highest
sensitivity and specificity among other [41].
3.2.1 Luminometric analysis of neutrophil reactive oxygen species gen-
eration
Luminol was used for chemiluminescence assay to determine the production of
reactive oxygen species (ROS)[41]. Krebs-ringer buffer was prepared by dissolving
one bottle of KRB buffer (Sigma-Aldrich, Schnelldorf, Germany) in 1 L distilled
water and adding 1.26 g sodium bicarbonate and serum albumin (1 g / 100 ml) and
this buffer was used to resuspend neutrophils were isolated from human buffy coat
by dextran-sedimentation and Ficoll-Paque gradient centrifugation protocol.
Luminol was dissolved in 10 ml DMSO, then added to 1 L of 0.1 M of NaOH. In
brief, 96-well microplate was used. In each well was pipetted 200 µl reaction mixture
as fowloing:
1. 100 µl luminol solution (0.5 mM) included SOD (5000 U/ml) and catalase (200
000 U / ml).
2. 100 µl Neutrophil cells suspension (106 cells /ml).
Neutrophils were pretreated with different concentrations of LL-37 (5, 10, 20, and
30 µg / ml) and incubated at 37 °C for 30 minutes with shaking, some samples were
not pretreated with LL-37 used as control and blank was performed by applying all
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reagents without neutrophils cells. The emission of light was recorded for 1 hour
(one measurement each 3 minutes) by a luminometer (Magellan; Chantilly, VA,
USA) after triggering ROS production by adding PMA (100 nM) (Sigma-Aldrich,
Taufkirchen, Germany) or Staphylococcus aureus (104 CFU/ml).
3.2.2 Detection of intracellular ROS from human neutrophils by flow
cytometry
Human neutrophils isolated from buffycoat were gated depending on their SSC
and FSC characters and labeled with two different antibodies FITC-labeled mouse
anti-human CD66 and PreCP-labeled mouse anti-human CD45 (Becton-Dickinson,
Heidelberg, Germany) for compensation and remove false light detections.
The cells were resuspended in Krebs-ringer buffer containing 100 µM 2´,7´
dichlorofluorescin diacetate (DCFDA; Fluka, Steinheim, Germany) and cells sus-
pension 106cells/ml was incubated without/with various concentrations of LL-37 or
sLL-37 for 30 minutes[185]. The ROS products were triggered by PMA (100 nM)
and their fluorescence analyzed by flow cytometry (Becton-Dickinson, Heidelberg,
Germany).
The mean fluorescence intensity of at least 105 neutrophil cells was calculated
by the CELLQUEST software (Becton-Dickinson, Heidelberg, Germany). For each
experiment, unstained cells and cells treated with sLL-37 served as controls.
3.2.3 ROS Production by mouse neutrophils
Neutrophils were isolated from mouse peritoneal cavity and resuspend in Krebs-
ringer buffer included 1,26g sodium bicarbonate and serum albumin (1 g / 100 ml)
after red blood cells were lysed and cells were washed for several times in PBS.
Luminol solution (0,5 mM) was prepared by dissolving luminol in 10 ml DMSO
which was added into 1 l of 0.1 M NaOH[41].
In each well of 96 well- plate 100 µl of neutrophils suspension (6 x 106 cell/ml) was
mixed with 100 µl of luminol solution (0,5 mM). The ROS production was triggered
with Staphylococcus aureus 104 CFU/ml. The emission of light was recorded for 1
hour (one measurement each 3 minutes) using a luminometer under shaking and
37C°.
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3.3 Evaluation of neutrophil phagocytic activity
To investigate the role of cathelicidin in modulating phagocytosis activity of neu-
trophils, the uptake of bacteria by neutrophil was evaluated depending on the basic
principle of phagocytosis assay is to incubate neutrophils with the target particle,
and then monitor the rate of either target ingestion or its loss from the medium.
Microscopy is the most direct approach when measuring phagocytosis. The
percentage of neutrophils ingesting bacteria can be determined using microscopy
and flow cytometry [70].
3.3.1 Evaluation of neutrophil phagocytic activity by microscopic method
Human neutrophils were isolated using dextran sedimentation and Ficoll-Paque
gradient centrifugation protocol as mentioned above. The isolated cells were washed
with PBS two times and resuspended (106/ml) in Krebs-Ringer phosphate buffer (pH
7.3) containing glucose (10 mM), Ca2+ (1 mM), and Mg2+(1.5 mM), and 0.3% BSA
(to minimize cellular aggregation) and then preincubated at 37 °C for 10 min in the
presence of different concentrations of LL-37 (1, 5, 10 and 20µg/ml). The opsonized
Staphylococcus aureus were incubated with neutrophils 106 CFU/ml at ratio of 1:
25 (neutrophil: bacteria). Adding bacteria took place in polypropylene tubes with
slowly tumbling at 37 °C for 1 hour.
After incubation the cells were subjected to repeated washes in PBS (110 g, for
10 min, to remove nonattached bacteria) and resuspended in RPMI 1640 medium
supplemented with 10% heat-inactivated FCS.
Cytospin was performed to determined microscopically the uptake of bacteria
by neutrophils. After cytospin, slides were air dried overnight, fixed in methanol
(5min), Giemsa stained, and mounted. Slides were studied using oil immersion and
1000 magnification, and the number of bacteria/cell was counted for the first 50
positive cells (Figure 3.3.1) [29].
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Figure 3.3.1: Giemsa-stained slides of neutrophils after 1 h. incubation with LL-37 resistant
opsonized Staphylococcus aureus. (A) Negative control, human neutrophils were inactivated by formalin before
incubation. (B) Positive control, bacteria were incubated with active human neutrophils. (C) stimulated human
neutrophils with 5µg/ml LL-37 were incubated with bacteria. (D) stimulated human neutrophils with 10µg/ml
LL-37 were incubated with bacteria.
Phagocytosis is expressed as mean number of bacteria (bound or ingested)/cell
[29]. Positive and negative controls were performed (negative control = inactive neu-
trophils were fixed with 3.7% formaldehyde before incubation with bacteria, positive
control = active neutrophils were incubated with bacteria without preincubation
with LL-37).
3.3.2 Evaluation of neutrophil phagocytic activity by flow cytometric
method
Human neutrophils isolated from buffycoat and cathelcidin-resistant Staphylo-
coccus aureus were used for this measurment. Staphylococcus aureus 105CFU/ml
were labeled with FITC and opsonized with heat-inactivated human serum.
The neutrophils were preincubated with or without variant concentrations of LL-
37 or sLL-37 used to exclude a nonspecific effect of LL-37 served as control. Human
serum opsonized and FITC-labeled bacteria were incubated with human neutrophils
at 37 °C for 30 minute (shaking 200rpm) at ratio of 1: 25 (neutrophil: bacteria).
Then cells were resuspended in CellFix (BD PharMingen, Erembodegem, Bel-
gium) and treated with 500µL of Trypan blue (400 mg/mL prepared in 0.85% saline
solution) to quench the fluorescence of the bacteria bound on the surface.
Efficient quenching was confirmed on negative controls. The percentage of phago-
cytosing cells (bearing green fluorescence) was determined based on the negative
control and autofluorescence and analyzed by flow cytometry (Becton-Dickinson,
Heidelberg, Germany)[79].
Neutrophil cells were gated depending on their SSC and FSC characters and
labeled with two different antibodies FITC-labeled mouse anti-human CD66 and
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PreCP-labeled mouse anti-human CD45 (Becton-Dickinson, Heidelberg, Germany)
to make compensation and remove false light detections. A 488 nm argon laser beam
was used for excitation.
The mean fluorescence intensity of at least 105 neutrophil cells were calculated by
the CELLQUEST software (Becton-Dickinson, Heidelberg, Germany). Each assay
was performed in duplicate and all results were expressed as the mean + standard
error of the mean of four to eight independent assays.
3.4 Assessment of lung tissue repair and emphysema induc-
tion in presence of cathelicidin
To study the role of cathelicidin in reducing emphysema induction and enhanc-
ing airway epithelium healing, two models were performed: the elastase-induced
pulmonary emphysema and naphthalene-induced lung injury models.
3.4.1 Induction of specific lung injury and evaluation of airway epithe-
lium regeneration
Clara cells were ablated in mice by cytoselective toxicity of the metabolic prod-
ucts of naphthalene produced by cytochrome P450 mono-oxygenase [128].
Acute lung injury was induced in murine lungs by intraperitoneal injection of
naphthalene. Plopper and colleagues [128] reported that intraperitoneal administra-
tion of naphthalene is a specific toxicity to Clara cells and does not cause changes in
other type epithelial cells, indicating that the toxicity of naphthalene to Clara cells
is cytoselective. Stripp et al. [152] reported that treatment with naphthalene at a
concentration of 300 mg/kg results in the ablation of clara cells in the bronchiolar
region for at least 20 days in mice [152].
To investigate whether the endogenous cathelicidin enhances lung tissue healing,
an acute lung injury induced in mice by naphthalene and the growth of destroyed
airway epithelium was observed and evaluated during time for 15 days after lung
injury was induced (first, fifth and fifteenth day) .
Clara cells or ciliated cells of cell-specific 10-kD a protein (CC10) density was
determined during time by immunohistochemistry after specific epithelial injury by
naphthalene.
Naphthalene was purchased from Fisher (Aschaffenburg, Germany) and dis-
solved in corn oil by overnight shaking 80 rpm at room temperature. Wild type
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and CRAMP deficient SVJ129 mice (Pathogen-free, male, weighing 25–29 g and
aged 8–10 weeks) were intraperitoneally injected with naphthalene 200 mg/kg body
weight or corn oil alone with equivalent volume as vehicular control and after in-
jection; mice were maintained in pathogens-free condition. On 1, 5 and 15 days
later, four groups from mice: WT control, WT naphthelene, CRAMP-KO control
and CRAMP-KO naphthelene were sacrificed (n =6 in each group).
The tracheas were exposed and cannulated, the lungs were removed and fixed
with 6% paraformaldehyde perfusion with steady flow for 20 minute. The lungs
were cut in the same orientation after they were embedded in agarose to keep the
distance between septa of airway space. Then lung tissue sections were dehydrated
and embedded in paraffin. This Sections of airways with 3 µm in thickness were
deparaffinised in xylene and rehydrated in ethanol and PBS.
Endogenous peroxidase activity was inactivated using 1% hydrogen peroxide in
methanol (Roth, Karlsruhe, Germany; pH 7.2) for 30 minute. Antigen retrieval was
performed by microwave treatment in 3% citrate buffer (Roth; pH 6.0).
After washing in PBS, the sections were incubated in PBS containing 1% bovine
serum albumin (Serva, Heidelberg, Germany) for 30 min followed by incubation
with a polyclonal rabbit antibody (courtesy of J. Klug, Justus Liebig University,
Marburg, Germany) directed against (CC10) diluted 1:3,000 in the same solution
for 1 hour at 37 °C.
Sections were then incubated with an anti-rabbit secondary antibody diluted 1:10
for 30 minute at room temperature. This was visualised using 3,3’ diaminobenzidine
as chromogen according to the ABC method (Vectastain Elite ABC Kit; Vector
Laboratories, Burlingame, CA, USA) and following the manufacturer’s instructions.
All sections were counterstained with hematoxylin and eosin (H&E).
A quantitative analysis was performed by drawing manually a line of 1000µm
over basement membrane using the computer mouse, and stained Clara cells were
counted. The index of CC10/ml basement was used to compare between CRAMP
deficient as parameter for regeneration (Figure4.5.1) .
3.4.2 Elastase-induced pulmonary emphysema in mouse
All mice used in this study were male, from SVJ129 background, 6- to 8-weeks
old and maintained in our animal facilities under specific pathogen-free conditions.
The CRAMP-deficient and their wildtype mice were anesthetized and given an in-
tratracheal instillation of 70 U/Kg elastase (Sigma, Steinheim, Germany) in 0.08 ml
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of sterile PBS or 0.08 ml of PBS alone served as controls.
This dose of elastase was repeated after 10 days, this two doses of elastase were
given to both CRAMP deficient and their wildtype mice (n=6-8 mice in each group).
On the day 30th from the first dose of elastase administration, mice were anes-
thetized by i.p. injection of 50 mg/kg body weight ketamine hydrochloride (Ketan-
est, Parke Davis; Berlin) and scarified.
Then tracheas were exposed and cannulated, then the cannulated tracheas with
lung were removed together and inflated with 6% paraformaldehyde perfusion with
steady flow for 20 minutes. The lungs were cut in the same orientation after they
were embedded in agarose to keep the distance between septa of airway space without
change.
Then lung tissue sections were dehydrated and embedded in paraffin. Sections
of 2-µm thick were stained with H&E. Air space enlargement was quantified by the
mean linear intercept (Lm) in 20 randomly selected fields of lung tissue sections
[134].
Calculation of mean linear intercepts (Lm), an estimate of the average distance
between the opposing walls of a single alveolus was briefly performed as following:
the photomicroscopic images were taken using digital sight (Olympus, Germany).
Horizontal and vertical lines were drawn in the images, and intercepts of air-
way walls with these lines were measured and length of mean linear intercept was
estimated by software (Figure 3.4.1).
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Figure 3.4.1: Air space enlargement was quantified by the mean linear intercept (Lm).
Representative histological sections hematoxylin/eosin-stained (x 40). Left: mouse lung treated
with PBS. Right: mouse lung treated with elastase. Emphysematous lung (right) shows air space
enlargement.
3.4.3 Bronchoalveolar lavage of elastase-induced pulmonary emphysema
in mice
After variant times 12 hours, 3, 6, 30 days of elastase administration in mice,
the bronchoalveolar lavage fluid (BALF) was performed.
In brief, the tracheas were exposed and cannulated, then lungs were lavaged with
3 ml (three times with 1ml each time) of PBS, and BALF was centrifuged at 1500
rpm for 15 minutes, and the supernatants were stored at -20°C until ELISA analysis.
The cells pellets were resuspended with 3 ml PBS and total cells in BALF were
counted by cells counter (GAZY, Germany). Cytospin specimens were obtained
by centrifugation at 500 rpm for 10 minutes and cytospin slides were stained with
Giemsa and the inflammatory cell fractions were evaluated by standard light micro-
scope.
3.4.4 Statistical analysis
For all experiments, at least triplicate determinations were made for each exper-
imental condition. In indicated cases, the results of representative experiments were
shown. All data are expressed as mean and standard deviation (SD).
Comparisons between experimental groups were performed using Student’s t test
and ANOVA test. Results were considered statistically significant for P values less
than 0.05.
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4 Results
4.1 LL-37 decreases the release of proinflammatory media-
tors from activated neutrophils
Cathelicidin modulates the response of monocytes / macrophages to endotoxin
[138]. To investigate whether this effect of cathelicidin is also effective on neutrophils,
we added 100 ng / ml LPS to human neutrophils perincubated with the human
cathelicidin LL-37 in different concentrations.
The release of the proinflammatory cytokines IL-1ß, IL-6, IL-8, and TNF-a was
significantly decreased in presence of LL-37 as compared to the samples stimulated
with LPS in absence of LL-37 (Figure 4.1.1) This effect of LL-37 was dose dependent.
(a) (b)
(c) (d)
Figure 4.1.1: LL-37 modulates inflammatory reactions of neutrophils in re-
sponse to LPS. LL-37 at the indicated concentration reduces the release of TNF-α (A), IL-1ß
(B), IL-8 (C), and IL-6 (D) after stimulation with 100 ng / ml LPS. Cytokine concentrations were
determined 12 hours after stimulation. * = p < 0.05, n = 6.
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These data show that LL-37 modulates the response of neutrophils to micro-
bial patterns. To investigate whether the effect of LL-37 is also effective when
whole bacteria are used to stimulate neutrophils, we incubated cells with heat in-
activated gram-negative Pseudomonas aeruginosa or gram-positive Staphylococcus
aureus. TNF-a in the supernatant was quantified by ELISA Figure 4.1.2 shows that
the secretion of this cytokine was significantly decreased in presence of LL-37.
(a) (b)
Figure 4.1.2: LL-37 decreases the release of proinflammatory mediators in re-
sponse to whole bacterial. (A) Neutrophils were incubated with 104 CFU/ml of Pseu-
domonas aeruginosa (P.a.) with or without 20 µg / ml LL-37 and TNF-α was measured after 12
hours. * = P < 0.05, n = 6. (B) Neutrophils were incubated with Staphylococcus aeurus (Sta. a.)
with or without 20 µg / ml LL-37 and TNF-α was measured after 12 hours. * = P < 0.05, n = 6.
4.2 LL-37 amplifies neutrophil ROS production
It has been demonstrated that LL-37 triggers ROS production in human neu-
trophils [12]. We assessed ROS production in response to PMA using luminometry
and flow cytometry. Time course of ROS levels were performed by chemilumines-
cence (Figure 4.2.1) and the ROS levels at 30 minutes were chosen for comparsion.
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Figure 4.2.1: Time course of ROS levels in human neutrophils trigged by PMA.
ROS levels were measured in human neutrophils (2 x 106cells/ml) by the luminol chemilumines-
cence method after PMA application at 37 °C for 60 minutes. The respiratory burst was triggered
by application of 100 nM PMA. (Blank = no cells, – Control = cells without PMA triggering; +
Control = cells + PMA). Time course revealed that the highest levels of ROS were at 30 min.
LL-37 significantly increased the ROS production in neutrophils triggered by
PMA in a dose dependent way as determined by luminol chemiluminescence (Figure
4.2.4). The results of this assay were perform at 37°C.
Figure 4.2.2: LL-37 amplifies ROS production in human neutrophils by chemi-
luminescence method. ROS levels were measured in human neutrophils (2 x 106 cells/ml)
by the luminol chemiluminescence method after PMA application. The respiratory burst was trig-
gered by application of 100 nM PMA. Blank = no cells, – Control = cells without PMA triggering;
+ Control = cells + PMA . Result reveals that the production of ROS triggered with PMA was
significantly amplified with LL-37 and this activity was dose-dependent. ANOVA with Tukey’s
test; * = P < 0.05, ** = P < 0.01, *** = P < 0.001..
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The amplification of ROS by LL-37 was also demonstrated using flow cytometry
measuring the fluorescence intensity of DCFDA-loaded neutrophils for 30 minutes.
The levels of ROS were significantly increased in the presence of LL-37. This effect
of the peptide was dose-dependent. sLL-37 was used to exclude a nonspecific effect
of LL-37 and which had no effect on ROS production (Figure 4.2.3, 4.2.4).
Figure 4.2.3: ROS release detected by Flow cytometry; representative his-
tograms. FACS analysis shows differences in fluorescence intensity between neutrophils without
LL-37 treatment (control) and neutrophils pretreated with LL-37 and both were treated with PMA
to trigger ROS release.
Figure 4.2.4: LL-37 amplifies ROS production in neutrophils measured by flow
cytometry. ROS levels were measured in 2 x 106cells / ml neutrophils by flow cytometry after
incubating neutrophils with DCFDA (1 hour after PMA application). LL-37 amplified significantly
the triggered respiratory burst of human neutrophils induced by 100 nM PMA and this amplifica-
tion was dose-dependent. sLL-37 had no effect. Control = cells without pretreatment with LL-37
+ PMA. * = P < 0.05, n = 6.
The presence of serum (fetal calf serum) partly inhibited the effect of LL-37
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(Figure 4.2.5). PMA is a stimulus that needs to pass the plasma membrane in order
to activate PKC.
Figure 4.2.5: The effect of serum on LL-37 activity as ROS amplifier. ROS levels
were measured in 2 x 106 cells / ml human neutrophils by luminol chemiluminescence method.
ROS was triggered by opsonised 104CFU/ml Staphylococcus aureus. Results reveal that LL-37
amplified significantly ROS levels. n = 6; ANOVA with Tukey’s test; * = P < 0.05, ** = P <
0.01, *** = P < 0.001.
Thus LL-37 could potentially induce the uptake of PMA. In order to demonstrate
that LL-37 also enhances ROS production induced by other agents, we exposed neu-
trophils to whole bacteria. LL-37 significantly increased the ROS production after
bacterial stimulation (Figure4.2.5 ). To reveal the activity of endogenous cathelicidin
we isolated peritoneal neutrophils from wildtype and CRAMP-deficient animals us-
ing the thioglycollate method as described in the method section. We found that
after application of PMA, neutrophils from CRAMP-deficient animals had signifi-
cantly lower levels of ROS (Figure 4.2.6).
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Figure 4.2.6: Cathelicidin amplified ROS in mouse neutrophils. Neutrophils were
isolated from CRAMP-deficient animals and ROS levels were measured by the luminol chemilumi-
nescence method after PMA application at 37 °C. results revealed that ROS in neutrophils from
wild type mice was significantly higher than CRAMP-deficient animals. n = 6; ANOVA with
Tukey’s test; ** = P < 0.01.
LDH release was determined as marker of cytotoxicity and no increased levels
were detected up to 30 µg/ml LL-37 (data not shown).
4.3 Endogenous murine cathelicidin CRAMPmodulates neu-
trophil function
CRAMP is the homologous molecule of LL-37 in mice [61]. Based on the pep-
tide’s structure, expression pattern and biological activity, this gene and its encoded
product CRAMP serve very similar functions as the human counterpart. To test
whether endogenousely expressed cathelicidin has similar effects as exogenousely
applied peptide, peritoneal neutrophils were isolated from CRAMP-deficient mice
(Figure 4.3.1).
And to determine whether CRAMP is released from neutrophils, we performed
Western blotting on cell supernatants and found the precursor and the cleaved pep-
tide in supernatants from stimulated and native cells (Figure4.3.1). And after stim-
ulation with LPS, neutrophils from CRAMP-deficient animals showed significantly
increased release of TNF-a (Figure 4.3.2 ).
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(a) (b)
Figure 4.3.1: Neutrophils isolated from peritoneal cavities of mice. (a) Cells iso-
lated from mouse´s peritoneal cavity and cytospin was performed and Giemsa-stained slides shows
that >95% was neutrophils. (b) western blot was performed for suppernatants form CRAMP-
KO and wild type neutrophils suspensions, bands reveals that CRAMP-KO mice did not release
CRAMP as wildtype mice did.
Figure 4.3.2: Endogenous cathelicidin modulates the neutrophil innate immune
reaction. Neutrophils were isolated from CRAMP-deficient animals, stimulated with LPS (50 /
100 ng / ml), and the release of TNF-α was measured in supernatants. Neutrophils from CRAMP-
knockout animals released significantly higher amounts of the cytokine as compared to the cells
from wildtype animals.
To test whether this suppression of inflammatory activation is associated with
a breach in antimicrobial activity, we performed bacterial killing assays applying
viable P. aeruginosa to neutrophils isolated from CRAMP deficient and wildtype
control mice.
We found that neutrophils from animals deficient in CRAMP have a significantly
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decreased antimicrobial activity (Figure 4.3.3). These data show that endogenous
cathelicidin modulates the response of neutrophils in responses of the innate immune
system.
(a)
(b)
Figure 4.3.3: Neutrophils from CRAMP-deficient animals showed a breach in
their innate host defense. (a) Neutrophils were incubated with Pseudomonas aeruginosa (1
neutrophil WT/KO : 1 bacterial cell) and the numbers of viable bacteria were analyzed by sampling
20 µl and plating on nutrient agar 30,60 and 90 min after bacterial inocculation. Control, bacte-
ria incubated with all experiment reagents in absence of neutrophils.Control shows increasing of
bacteria count (bacterial growth) in opposite of samples contain neutrophils. (b) neutrophils from
CRAMP-KO mice shows significantly lower bactericidal activity than neutrophils from wildtype
mice .* = P < 0.05, n = 6.
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4.4 Cathelicidin improves phagocytosis of human neutrophils
As mentioned in 4.3, the physiological presence of CRAMP improved signifi-
cantly the bactericidal activity of neutrophils. we wanted To test whether cathe-
licidin modulates the rate of phygocytotic uptake of bacteria into neutrophils, a
critical step in killing of microorganisms [54]. The phagocytosis of neutrophil was
investigated in presence of different concentrations of LL-37 by microscopic and
flow cytometric methods. microscopic assays [29] were performed to investigate
whether LL-37 modulates the uptake of bacteria into neutrophils. The catheli-
cidin peptide significantly increased the uptake of bacteria into neutrophil cells in
a dose-dependent manner (Figure 4.4.1). These data showed that exposure to the
cathelicidin peptide increases host defense activities such as ROS production and
engulfment of bacteria. The result of the microscopic method showed that the mean
numbers of bacteria (bound and ingested) in neutrophils treated with LL-37 was
significantly higher than non treated neutrophils (Figure 4.4.1).
Figure 4.4.1: Microscopic method to investigate the phagocytic activity of Neu-
trophils. Microscopic evaluation in presence or absence of LL-37 is expressed as mean numbers
of bacteria (bound or ingested)/ Neutrophil cell + SEM of three to six independent experiments.
Flowcytometric assay reveals also that LL-37 improves significantly phagocytic
activity of human neutrophils (Figure 4.4.2, 4.4.3).
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Figure 4.4.2: Phagocytic activity of human neutrophils measured by FACS; rep-
resentative histograms. Human neutrophils were inactived by treatment with paraformalde-
hyde served as -control and active neutrophils without pretreatment with LL-37 served as +control.
Figure 4.4.3: Evaluation of neutrophil phagocytic activity by flow cytometric
method. Negative control, 105CFU/ml of opsonized and FITC-labeled Staphylococcus aureus
were incubated with inactive human neutrophils. Positive control, 105 CFU/ml of opsonized and
FITC-labeled bacteria were incubated with active human neutrophils. Three groups, pretreated
human neutrophils with different concentrations of LL-37 (10 and 20µg/ml) incubated with 105
CFU/ml of opsonized and FITC-labeled Staphylococcus aureus. one group, pretreated human
neutrophils with sLL-37 was used to exclude a nonspecific effect of LL-37 incubated with opsonized
and FITC-labeled Staphylococcus aureus. Each assay was performed in duplicate and all results
were expressed as the mean + standard error of the mean of fluorescence index. Four to eight
independent assays were performed.
The results from both methods showed that the up take of bacteria by neutrophil
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was increased by adding LL-37 and this function of LL-37 was dose-dependent.
4.5 CRAMP enhances lung tissue repair
To examine whether CRAMP in lung tissue enhances healing in airway, selective
injury was induced to mouse nonciliated bronchiolar (Clara) epithelial cells with
naphthalene 200 mg/kg body weight or corn oil alone with equivalent volume (con-
trol). 1, 5 and 15 days later, mice were sacrificed and histological sections were used
for immunohistochemistry using antibodies directed against Clara (CC10 protein).
The proliferation was evaluated by counting Clara cells in one millimetre of
basement membrane depending on the expression CC10 as marker for differentiated
Clara cells. Sections showed that airway Clara cells were exfoliated after one day of
naphthalene administration (Figure 4.5.1). After 5 and 15 days, the regeneration of
lung tisssue was evaluated by measuring the density of Clara cells in one millimeter
of basement membrane. The result showed that the Clara cells density in airway
sections of CRAMP-knockout was significantly lower than wild type mice 15 days
after naphthalene administration (Figure 4.5.2, 4.5.3), it means that the healing of
lung tissue was signifigantly decreased in the absence of cathelicidin..
Figure 4.5.1: In vivo naphthelene model and Clara cells regeneration. Moue lung
sections from naphthelene model were CC10 stained (immunohistochemistry) show how Clara
cells are intact in control samples and after one day from naphthelene injection Clara cells were
Exfoliated and regeneration started. adapted from experiments of this work.
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Figure 4.5.2: Immunohistochemical staining with anti-CC10 antibody shows
expression of the clara cell marker protein CC10 was observed in distal regions
of the airways. (A) Wild type control mice after intraperitoneal injection of only corn oil
vehicle (WT Control). (B) clara cell-ablated WT mouse one day after intraperitoneal injection of
naphthalene (C) clara cell-ablated WT mouse 5 days after intraperitoneal injection of naphthalene.
(D) clara cell-ablated wild type mouse 15 days after intraperitoneal injection of naphthalene.
(E) CRAMP knockout mice control after intraperitoneal injection of only corn oil vehicle (KO
Control). (F) clara cell-ablated CRAMP- knockout mouse after one day intraperitoneal injection of
naphthalene. (G) clara cell-ablated CRAMP- knockout mouse after 5 days intraperitoneal injection
of naphthalene. (H) clara cell-ablated CRAMP- knockout mouse after 15 days intraperitoneal
injection of naphthalene.
Figure 4.5.3: CRAMP enhances repair in mouse lung tissue. Morphometric analysis of
CC10-positive cells in wild type and CRAMP knockout mice after 15 days of naphthalene in-
traperitoneal injection showed that CRAMP increased significantly regeneration of Clara cells in
mice. Results are expressed as the means numbers of positive CC10/ 1000µm of bassment mem-
brane mean and SD (n=6 animals per group and time period).
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4.6 Cathelicidin protects from pulmonary emphysema in-
duction
The elastase-induced emphysema model has been used in research for more than
30 years and has brought considerable insight into the pathogenesis of human disease
[81]. Intratracheal instillation of elastase induced pulmonary emphysema in mice,
which was recognized by lung appearance and microscopic measurement of alveolar
erlargement (Figure 4.6.2).
Mice from the elastase groups (WT and CRAMP-KO) had emphysematous lung
form (see photo Figure 4.6.2), and the mean linear intercept for WT mice was
(85,51 ± 3,15µm, n=8) and for CRAMP-KO was (111,7 ± 6,850µm, n=8) markedly
increased compared with the PBS groups WT (33,68 ± 3,117 µm, n = 6; P = 0.0001)
and for CRAMP-KO (33,17 ± 1,5 µm, n = 6; P = 0.0001).
These results revealed that the presence of cathelicidin minimized significantly
induction of pulmonary emphysema in mice. (Figure4.6.2).
Figure 4.6.1: Picture of lungs from CRAMP-KO and WT mice. Some groups of mice
were treated with PBS (control) and other groups were treated with elastase (emphysema) and
these pictures showed that the lungs from groups were treated with elastase had emphysematous
appearance.
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(a)
(b)
Figure 4.6.2: Mean linear intercept (Lm) for emphysema and control mice
reveals that cathelicidin presence protects from elastase- induced pulmonary
emphysema in mice. (a) Histological sections stained hematoxylin and eosin (H and E)
shows mean linear intercept (Lm) for emphysema and control mice after 1 month of elastase or
PBS treatment. Lm was measured at the same magnification x400 demonstrates airway spaces
erlagement in lungs of elastase groups.(b) Lm expressed as mean and SD for the whole lungs. (n=8
animals per group and time period).
To investigate whether the anti-inflammatory activity of cathelicidin is responsi-
ble of reducing elastase- induced pulmonary emphysema. BALs were collected from
(WT and CRAMP-KO) mice after 12 hours, one, 3, 6 days and one month from
intratracheal instillation of elastase. Total count of cells per one milimetre and in-
flammatory cytokine TNF-a in BALs were measured. The results showed that the
total number of cells and the concentration of TNF-a in response to intratracheal
instillation of elastase were significantly higher in BAL of CRAMP-KO mice than
WT mice (Figure 4.6.3).
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(a) (b)
(c) (d)
(e)
Figure 4.6.3: The anti inflammatory activity of cathelicidin could be the reason
of reducing the induction of pulmonary emphysema in mice. (a) Total cells number
in BAL of CRAMP-KO mice are significantly higher as compared to WT mice after 30 days of
treatment with two doses of elastase. (b) The total cells number in BAL of CRAMP-KO mice
are significantly higher than WT mice after 3 days of treatment with one dose of elastase. (c)
Differential cell count of BALs from CRAMP-KO and WT mice after 30 days of treatment with
two doses of elastase. Result revealed that the majoraty of cells was macrophages. (d) Cells
differentiation of BALs from CRAMP-KO and WT mice after 3 days of treatment with one doses
of elastase. Result revealed that the majoraty of cells was neutrophils and the neutrophils ratio
in BALs of CRAMP-KO mice were significantly higher than WT mice. (e) shows that the release
of TNF-α detected in BALs from CRAMP-KO mice teated with elastase to induce emphysema
was significantly higher than WT mice. All results expressed as mean and SD. (n=6 animals per
group). 63
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5 Discussion
The main findings of the present study are: (1) modulating the inflammatory
reaction of neutrophil to avoid the exaggerated reaction of neutrophils in response
to bacteria or their commponents; (2) improvement of bactericidal activity of neu-
trophils by amplifying ROS release and phagocytosis; and (3) provide protective
action against pulmonary emphysema and acute lung injury. In brief, this findings
revealed cathelicidin as homeostasis of inflammation and repair processes.
5.1 Cathelicidin modulates inflammatory responses of neu-
trophils
One finding of the present study is the activity of the cathelicidin peptide LL-37
to modulate the activation of neutrophils stimulated by bacterial patterns. Exoge-
nousely applied peptide as well as endogenousely, physiologically expressed peptide
have this effect on neutrophils. These data support the role of cathelicidin peptide
in the modulation of innate immune responses.
Cathelicidin peptides are known to impact on inflammatory mechanisms rel-
evant in infection and sepsis [7, 161]. Peptide application and overexpression of
the peptides’ genes have been used in various sepsis models and demonstrated that
cathelicidins inhibit overreactive responses to microbial patterns [138, 12, 161, 83].
The underlying mechanisms likely involve the modulation of the responses of host
defense cells to microbial patterns. While it has been already known that cathelicidin
modulates the response of macrophages [138, 106] and DCs [80] to TLR-ligands, the
effect on neutrophil activation has been less clear. Our results show that cathelicidin
modulates the response of neutrophils to endotoxin and to whole bacteria.
Releasing of a various proinflammatory mediators (IL-1ß, IL-6, IL-8, and TNF-a)
was significantly decreased suggesting that the peptide protects from the develop-
ment of a cytokine storm.
This effect was also detectable when whole Gram-positive and –negative bacteria
were applied, indicating that the cathelicidin’s effect was also effective in the inter-
action of neutrophils with biologically relevant microorganisms. Interestingly, also
endogenous cathelicidin had this modulatory effect on cytokine release as shown in
the experiments using neutrophils from CRAMP-deficient mice.
The study of Zheng et al. [185] found increasing IL-8 release at high concentra-
tion of LL-37 (20 and 40 µg/ml). This study did not investigate the combination
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of LPS and LL-37. In the present study, we did not find an increased release of
cytokines at concentrations of 5-20 µg/ml or evidence of cell lysis as measured by
LDH release.
5.2 Cathelicidin presence amplifies bactericidal activity of
neutrophil
In addition to the release of inflammatory mediators, cathelicidin modulates
other cellular processes including cell death pathways and the production of ROS.
Cathelicidin has a complex effect on neutrophil apoptosis. Cathelicidin modulates
apoptosis via the receptors formyl peptide receptor like 1 (FPRL1) [112] and P2X7
[16], while different methodology revealed induction of secondary apoptosis [184].
Cathelicidin is known to interfere with the pathways that regulate the production
of ROS in myeloid cells including macrophages [186] and neutrophils [185]. We
confirmed these observations that application of LL-37 results in amplification of
PMA-triggered ROS production. ROS are considered important effector molecules
in the direct or indirect bactericidal activities of neutrophils [41]. The significant
decreasing of ROS production in CRAMP-deficient animals emphasizes the role of
the endogenous peptide in this process.
We therefore investigated whether the presence of cathelicidin is necessary for the
antimicrobial activity of neutrophils and found that CRAMP-deficient neutrophils
revealed significantly less antibacterial activity. While these data don’t discriminate
between different antimicrobial pathways of neutrophils, they show that catheli-
cidin increases antimicrobial activities of neutrophils while decreasing the release of
proinflammatory mediators.
Phagocytosis assay also reveal increased uptake of bacteria into neutrophils as
like as what was shown by Davidson study that LL-37 modified their phagocytic
function in dentritic cells [43]. It might be that phagocytosis improvement of hu-
man neutrophils after addition of LL-37 was related to bactericidal of CRAMP or
it could be possible that cathelicidin may prime neutrophils to face bacteria by in-
creasing their phagocytic activity. ROS- production and antimicrobial activity were
dependent on the endogenous peptide as demonstrated in the experiments with
murine cells.
Since the precursor and active form are released by neutrophils it is difficult to
speculate about the site of activity. In the living organisms, cathelicidin peptide from
different sources could contribute to the described effects on neutrophils. Several
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cell types produce the peptide, including epithelial [11] and immune cells [2]. Also
peptide synthesized in and secreted from neutrophils likely contributes.
The peptide’s effect of ROS production is partly inhibited by serum components.
This could indicate that the described mechanisms is not active in the blood, however
relevant for neutrophils that have immigrated into tissue and body surfaces.
The mechanism how cathelicidin modulates the function of myeloid cell types is
largely unclear. The peptide is capable to bind to LPS and decreases the detection
of this pattern by the receptor complexes [111, 133].
Additionally, the peptide likely interacts with cellular receptors, including FRPL1
[44], P2X7 [51], or epidermal growth factor receptor (EGFR) [157], with possible
downstream effects on inflammatory pathways [106].
The effectiveness of an all-D-form of the peptide together with observations of
altered cell membrane function and structure implies a more complex mechanisms in-
cluding interaction with biomembranes and modulation of the function underscoreof
membrane associated proteins [45].
Based on the current study and former data it is still difficult to shortly sum-
marize the role of cathelicidin in host defense immunity. In vitro studies revealed
a direct antimicrobial activity [3, 11] that is supported by the results of infection
models in CRAMP-deficient animals [38, 118].
Cathelicidin interacts with a number of cell types such as endothelial cells [87],
epithelial cells [157], mast cells [117], macrophages [138], and DCs [43, 80]. As shown
in the present study, cathelicidin modulates neutrophil functions by suppressing the
release of proinflammatory mediators and increasing antimicrobial activity.
Animal studies showed that cathelicidin protects from exaggerated inflamma-
tory reactions [83], however, also has proinflammatory roles in skin [173]. Based
on the current data, cathelicidin is an effector molecule of innate immunity with
diverse functions, including antimicrobial activity and modulation of wound repair
and inflammation.
5.3 Cathelicidin enhances repair of lung epithelial cells
Epithelium covers virtually all barrier organs. It is continuously exposed to
external environment, where microbes and secreted microbial products, potential
allergens, toxic substances and irritants are present. Epithelial injury is not a rare
event. Restoration of the barrier integrity after injury represents a fundamental de-
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fense function of epithelia. Epithelial repair process involves a stereotypical sequence
of events - epithelial restitution and regeneration [129].
Epithelial restitution starts immediately after injury and is characterized by
rapid migration of cells towards the wound area in order to re-establish surface
epithelial continuity. An increased migratory capacity of the cells is a result of
the de-differentiation process after injury [82] and may be explained by the loss of
contact inhibitory signals at the damaged area [55]. Rapid restitution after injury
limits fluid and electrolyte losses and prevents pathogens from the lumen getting
into local and systemic immune compartments [129].
Various factors initiate the repair process. They include (a) epidermal growth
factor (EGF) family members like EGF, transforming growth factor-alpha (TGF-a),
heparin binding EGF or amphiregulin [85]; other growth factors like keratinocyte
growth factor (KGF) [167], insulin-like growth factor-1 (IGF-1) [142], hepatocyte
growth factor (HGF) [178]; (b) inflammatory cytokines like IL-1 beta [67]; (d) ex-
tracellular matrix proteins (fibronectin, fibrinogen) and matrix metalloproteinases
[119]; and other factors.
Like in many other mucosal surfaces, epithelium of the airways has a great
capacity to repair itself after injury, as demonstrated in vitro [82, 177] and in vivo
[53].
Immediately (within 5-15 min) after injury, secretory, ciliated and (probably
also) basal ECs at the wound edge de-differentiate, spread and migrate across the
denuded basement membrane without any external stimulation or non-EC partici-
pation at a speed of about 2-3 microns/min [53].
Airway epithelium represents a physiological tissue barrier with two sides and
two functions. First, it protects the respiratory compartment of the lung from
pathogens by mechanical and chemical defense factors such as mucus, antimicrobial
substances, or beating of cilia.
Second, intact airway epithelium protects from developing inflammation in re-
sponse to microbes present in the airway lumen primarily by preventing the contact
of bacteria with subepithelial inflammatory cells (macrophages and DCs) which are
very sensitive to any kind of danger.
In addition to antimicrobial activity, several reports indicated that LL-37 is also
able to mediate cellular responses that contribute to the immune response and might
enhance the wound-healing process [13, 15]. LL-37 was shown previously to induce
migration of epidermal cells by transactivating the EGFR [160]. It was also shown
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to stimulate bronchial epithelial cell migration and proliferation [141].
It has been shown previously that re-epithelialization of organ-cultured skin
wounds is inhibited by antibodies against LL-37 in a dose-dependent mode [73].
The result of this study showed that the presence of cathelicidin physiologically can
enhance airway epithelium regeneration after lung injury in mice, which was induced
by naphthalene administration.
5.4 Cathelicidin protects from pulmonary emphysema
The biological functions of LL-37 have been extensively studied during the last
decade. As a result, many of its non-antimicrobial activities have been identified.
The peptide was implicated in chemotaxis of inflammatory and immune cells includ-
ing neutrophils, monocytes, lymphocytes [44], eosinophils [158] and mast cells [116].
LL-37 has been also shown to regulate tissue homeostasis: it stimulated regeneration
of skin wounds [73], induced angiogenesis [87], increased growth of breast [72] and
lung cancer cells [166].
For pathpogensis of pulmonary emphysema, it is possible that the destruction of
the lung parenchyma in pulmonary emphysema may be a result of chronic unopposed
oxidant stress, unopposed proteolysis, apoptosis, impaired clearance of apoptosed
cell bodies [165], cellular senescence without adequate cell replacement [121], or a
switch from an innate toward an autoimmune response [154].
An interesting finding of this study is that cathelicidin reduced elastase-induced
pulmonary emphysema in mice, which was demonstrated using morphometric pa-
rameter called airway linear intercept (Lm) to compare between lungs from CRAMP
knockout and wild type mice.
Cathelicidin could minimize pulmonary emphysema induction in mice through
firs either its anti-inflammatory function [161, 138, 83], where it is known that
inflammatory mechanism has essential role in inducing pulmonary emphysema [52,
4],or its anti-protease activity [179], so it inhibits elastase activity which in turn
reduces lung injury- induced pulmonary emphysema. Third the cathelicidin activity
enhances airway epithelium repair [73], as shown above (5.3) where the presence of
cathelicidin enhanced healing of lung injury.
Taken all together we conclude that the reason of difference in the induction
of pulmonary emphysema between wild type and CRAMP- deficient mice could be
related to one or all of cathelicidin activities mentioned above which participated
in reducing emphysema induction. according to previous findings we can hypothese
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that the susceptibility toward pulmonary emphysema could be higher in absent of
cathelicidin.
5.5 Conclusion
Inflammation is an integral part of reactions of the innate immune system. The
innate immune system is responsible for maintaining a functional and physical bar-
rier against microorganisms.
Overactive inflammatory responses often cause harm to the organism. Thus,
several layers of regulatory mechanisms modulate the effectors of innate immunity
to balance between host defense and inflammation. Neutrophils are one of the most
prominent effector cells of the innate immune system [97].
They are recruited to the site of infection and are equipped with various an-
timicrobial effector mechanisms, whose role in host defense has been demonstrated
for many pathogens. Antimicrobial peptides (AMPs) are effector molecules of the
innate immune system with direct antimicrobial activity [183].
The defensins and the cathelicidins are the two prototypical families of AMPs ex-
pressed in mammals. AMPs are expressed in epithelial and professional host defense
cells such as macrophages or neutrophils. In addition to their role as antibiotics,
AMPs have diverse activities on various cell types [174]. LL-37/hCAP-18 is the only
cathelicidin present in humans and has several regulatory activities [181].
LL-37 is the C-terminal cleavage product that carries the biological activity. The
precursor hCAP-18 is found in the specific granules of neutrophils and is expressed
in many immune and epithelial cells. Cathelicidin has an established role in host
defense [38, 118].
In addition to their direct antimicrobial function, cathelicidin peptides are in-
volved in the modulation of repair and tissue homeostasis: augmentation of an-
giogenesis by a direct effect on endothelial cells [87], epithelial wound healing [73],
chemoattraction of immune cells [13], release of inflammatory mediators from ep-
ithelial cells by transactivation of the epidermal growth factor receptor (EGFR)
pathway [157].
A number of reports showed that cathelicidins act on myeloid cells. LL-37 sig-
nificantly up-regulates the endocytic capacity, modifies expression of phagocytic
receptors, and increases secretion of Th1-inducing cytokines of dendritic cells (DCs)
generated from blood monocytes [43].
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LL-37 modulates the response of monocytes and DCs to TLR – ligands [80, 45].
Also effects of cathelicidins on neutrophils have been described. One study showed
that LL-37 induces the generation of reactive oxygen species from human neutrophils
[185].
Taken together, these findings which are discussed above let us to conclude that
the cathelicidin could modulate and control many of the immunological reactions
of neutrophils in response to bacteria and their components. In addition to reduc-
ing inflammation, cathelicidin improved bactericidal of neutrophils by amplifying
reactive oxygen species and increasing phagocytosis.
The present study also showed that cathelicidin in physiological levels enhances
airway epithelium repair after acute lung injury in mice induced by naphthalene and
protectes from the induction of pulmonary emphysema in mice.
Further studies are undoubtedly necessary to reveal the physiological relevance
of these data in order to translate the knowledge about “Cathelicidin as an immuno-
logical modulator” into clinically meaningful information.
This might be important for further progress in the development of novel thera-
peutic and diagnostic approaches to diseases (lung infection, acute respiratory dis-
tress syndrome and COPD), which are associated with concomitant immune dys-
regulation and epithelial tissue injury.
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